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Abstract: The chemical investigation of marine mollusks has led to the isolation of a wide variety of
bioactive metabolites, which evolved in marine organisms as favorable adaptations to survive in different
environments. Most of them are derived from food sources, but they can be also biosynthesized de novo
by the mollusks themselves, or produced by symbionts. Consequently, the isolated compounds cannot
be strictly considered as “chemotaxonomic markers” for the different molluscan species. However, the
chemical investigation of this phylum has provided many compounds of interest as potential anticancer
drugs that assume particular importance in the light of the growing literature on cancer biology and
chemotherapy. The current review highlights the diversity of chemical structures, mechanisms of action,
and, most importantly, the potential of mollusk-derived metabolites as anticancer agents, including those
biosynthesized bymollusks and those of dietary origin.After the discussion of dolastatins and kahalalides,
compounds previously studied in clinical trials, the review covers potentially promising anticancer agents,
which are grouped based on their structural type and include terpenes, steroids, peptides, polyketides and
nitrogen-containing compounds. The “promise” of a mollusk-derived natural product as an anticancer
agent is evaluated on the basis of its ability to target biological characteristics of cancer cells responsible
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for poor treatment outcomes. These characteristics include high antiproliferative potency against cancer
cells in vitro, preferential inhibition of the proliferation of cancer cells over normal ones, mechanism of
action via nonapoptotic signaling pathways, circumvention of multidrug resistance phenotype, and high
activity in vivo, among others. The review also includes sections on the targeted delivery ofmollusk-derived
anticancer agents and solutions to their procurement in quantity. C© 2016 The Authors Medicinal Research
Reviews Published by Wiley Periodicals, Inc. Med. Res. Rev., 37, No. 4, 702–801, 2017
Key words: mollusk; cancer; preclinical evaluation; treatment; innovative mechanism of action; targeted
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1. INTRODUCTION
A. Cancer Epidemiology and Treatment
As emphasized by Torre et al.1 the occurrence of cancer is increasing because of the growth
and aging of the population, as well as an increasing prevalence of established risk factors such
as use of tobacco products, obesity, physical inactivity, and changing reproductive patterns
associated with urbanization and economic development. About 14 million new cancer cases
and more than 8 million deaths occurred in 2012 worldwide.1
In contrast to benign tumors, which with few exceptions2 do not invade other sites in the
body, cancer is a malignant tumor that is characterized by local tissue invasion and/or distant
metastatic processes. At early stages of cancer development, surgery or surgery in combination
with adjuvant radiotherapy are curative in most cases. Once the cancer is more developed and
has invaded other tissues, systemic chemotherapy (oral or intravenous) is added to surgery and
radiotherapy to eliminate isolated cancer cells and/or cancer cell subpopulations that have not
been removed or destroyed. As a general rule (always with exceptions), the more advanced
the cancer at the time of diagnosis, the more aggressive the adjuvant chemotherapy or poly-
chemotherapy that will be applied. Apart from chemotherapy, a number of other treatments are
often used, such as immunotherapy3–5 and photodynamic therapy.6,7 Doroshow and Kumar8
state that more extensive molecular characterization of tumors and their supporting matrices
are anticipated to become standard aspects of oncological practice, which will permit the design
of the treatment type for each individual patient and its continuous reevaluation during the
course of the treatment.
Paul Ehrlich, the founder of chemotherapy, who received the Nobel Prize for Physiology or
Medicine a century ago, postulated the creation of “magic bullets” to be used as chemotherapeu-
tic agents in the fight against human diseases.9 Unfortunately, such magic bullets are generally
ineffective in oncology. One reason is related to the fact that, for the most part, cancers are het-
erogeneous and consist ofmultiple cell subpopulations.10–12 Combinations of various anticancer
therapies (including polychemotherapies) involving drugs with different mechanisms of action
are thus widely used.13 In addition, chemotherapy and hormone therapy have been combined
with immunotherapy for the treatment of various solid cancers.14,15 The US Food and Drug
Administration (FDA) recently approved the first “immunotherapy combo,” the Bristol–Myers
Squibb’s combination of nivolumab and ipilumab, for the treatment of metastatic melanoma.16
B. Cytotoxic Versus Targeted Anticancer Therapies
Most chemotherapies consist of the use of cytotoxic drugs or molecularly targeted agents.
Each type of therapy could be effective in the treatment of patients whose cancer has reached
an advanced clinical stage and often these therapies are used in combination. However, for
certain cancer types, current chemotherapeutic standards seem still to rely mainly on cytotoxic
drugs (postsurgery and/or radiotherapy). This is the case, for example, for pancreatic cancer,17
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advanced stage small cell lung cancer (SCLC),18 and glioblastoma (GBM).19 In their review
entitled “An anticancer strategic dilemma: to kill or to contain,” Perret and Uzzan20 classify
the use of cytotoxic compounds as “killing” tools and targeted therapies as containment tools,
where the latter is aimed at the induction or extension of tumor dormancy.
Another difference between cytotoxic and targeted therapeutics consists of the way by
which the compounds are discovered and developed.Many cytotoxic compounds are discovered
from plants, fungi, or animals (especially from marine invertebrates) using bioactivity-guided
isolation, while targeted agents are typically designed and synthesized by researchers. Bioassay
guided isolation of natural extracts, when successful, leads to the discovery of novel peptides,
proteins, polysaccharides, lectins, small molecules, or other agents whose growth inhibitory
activity is first assayed in vitro in normal and cancer cell lines and then in vivo in various
murine syngeneic and/or human xenografted models. During these pharmacological (and
early toxicological) evaluations, it is rarely possible to decipher the mechanism(s) of anticancer
action. Targeted therapies, on the other hand, mainly rely on the screening of libraries of
compounds against a specific target protein that is usually intracellular. Researchers have also
developed biological agents (such as antibodies and nucleic acid aptamers) to target specific
proteins that are usually presented extracellularly and are typically involved in cancer cell
biology and/or characteristic of the tumor microenvironment.
C. Cancer Resistance to Chemotherapy
As will be seen later in the review, mollusk metabolites are evaluated based on the ability of
these natural products to overcome cancer cell resistance to chemotherapy, a property which,
in our view, makes a particular compound a promising anticancer agent. We thus summarize
below some of the major mechanisms of cancer cell resistance to chemotherapy that generally
lead to dismal prognoses. These discussed mechanisms are of most relevance to the compounds
presented in the current review. It must however be emphasized that there exist many more
types of cancer drug resistance, which are not mentioned herein. These, for example, include
the involvement of noncoding RNAs and multiple repair mechanisms,21 such as DNA base
excision22,23 and DNA double-strand break,24 among others.
1. The Multidrug Resistance (MDR) Phenotype
Chen et al.25 emphasize that one of the common mechanisms for cancer cells to resist cyto-
toxic insults is the overexpression of the ATP-binding cassette (ABC) efflux transporters such
as P-glycoprotein (P-gp/ABCB1), MDR-associated protein 2 (MRP2/ABCC2), and breast
cancer resistance protein (BCRP/ABCG2). These mechanisms belong to the so-called MDR
phenotype and limit the prolonged and effective use of chemotherapeutic drugs. For example,
P-gp overexpression in cancer cells leads to the decreased uptake of the drug and intracellu-
lar drug accumulation, minimizing drug–target interactions.26 As emphasized by Cui et al.,27
the superfamily of human ABC transporters comprises seven subfamilies with 48 members,
which exclude structurally and/or functionally unrelated drugs.26 Dinic et al.26 report that
there are two types of MDR: intrinsic and acquired. These authors26 further report that tu-
mor microenvironment-induced selection pressure leads to the development of intrinsic MDR,
while acquired resistance is a consequence of chronic chemotherapy administrations. Cort
and Ozben28 as well as Dinic et al.26 state that natural product-based drugs are important in
overcoming or reversing MDR in cancer therapy.
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2. The Resistance to Targeted Therapies
Schmitt et al.29 recently reviewed the preexisting subclonal resistance mutations to various
molecularly targeted agents that lead to clinical failures in the treatment of cancer patients
with targeted therapies. In addition, as mentioned earlier in this review and also discussed
Schmitt et al.,29 the problem of cancer heterogeneity leads to the inability of a single agent,
whatever it may be, to kill all the subclones and the associated populations in a given can-
cer. Schmitt et al.29 accordingly state that early detection of preexisting or emerging drug
resistance could enable more personalized use of targeted cancer therapy, as patients could
be stratified to receive the therapies that are most likely to be effective. Further, Kim30 re-
cently reviewed the mechanisms of resistance to targeted therapy, with a focus on acquired
resistance involving mutations and amplification of genes in the same or parallel signaling
pathways. This author also emphasizes that sequencing of primary tumors has revealed that
therapy-resistant clones already exist prior to targeted therapy, demonstrating once again
that tumor heterogeneity in primary tumors confers a mechanism for inherent therapy re-
sistance. Pazarentzos and Bivona31 also recently reviewed an important aspect of tumor re-
sistance to targeted therapies involving the adaptive stress signaling process. They discussed
the early adaptive changes by which tumor cells respond to the stress of a targeted ther-
apy that may be crucial for tumor cell survival during treatment and the development of
resistance.
An international task force of 180 scientistswas recently assembled to explore the concept of
a low-toxicity “broad-spectrum” therapeutic approach that could simultaneously target many
key pathways and mechanisms.32 Block et al.32 report that using cancer hallmark phenotypes
and the tumor microenvironment to account for the various aspects of relevant cancer biology,
interdisciplinary teams reviewed each hallmark area and proposed a wide range of high-priority
targets (74 in total) that could be modified to improve patient outcomes. For these targets,
corresponding low-toxicity therapeutic approaches were then suggested, many of which were
phytochemicals.32
3. Cancer Stem Cells (CSCs)
Several theories attempting to explain “the origin” of cancer(s) have been proposed. Some
theories attribute cancer to problems in developmental biology and cell differentiation,33–35
while others point to a normal cell undergoing tumorigenic transformation as a result of
genetic mutations.36,37 In fact, some of these ideas were published in the early 1900s,38,39
half a century before the solving of the DNA structure.40,41 Regardless of its origin, as em-
phasized by Rycaj and Tang,37 an established clinical tumor is sustained by subpopulations
of self-renewing cancer cells, operationally called CSCs that can intraclonally generate both
tumorigenic and nontumorigenic cells. Pattabiraman and Weinberg42 report that since their
identification in 1994, CSCs have been demonstrated to be directly implicated in resistance
to conventional anticancer therapeutics. Skrbo et al.11 have also recently revisited the sci-
entific background of the CSC theory. In their recent review, Pattabiraman and Weinberg42
also propose ways to use the current knowledge of the complex biology of CSCs to design
novel therapies to eliminate these cells. As detailed in Section 1.C.3, CSCs are implicated in
both minimal residual disease (the major cause of cancer recurrence) and metastasis.43 Dragu
et al.44 in their recent review discuss targeting CSC surface biomarkers, signaling pathways
that regulate CSC self-renewal and differentiation, drug-efflux pumps involved in apoptosis
resistance, and microenvironmental signals that sustain CSC growth, as well as manipulation
of miRNA expression and induction of CSC apoptosis and differentiation as strategies for
hampering CSC regeneration and cancer relapse. These authors44 also report that several anti-
CSC agents are under evaluation in preclinical and clinical studies, with most of them being
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designed to be used in combination with traditional therapies. Lisanti et al.45 are developing
strategies to eradicate CSCs using mitochondria targeting46 or through inhibition of protein
synthesis.47
4. Hypoxia
Span and Bussink48 recently discussed that: (i) hypoxia is a heterogeneous effect with oxygen
tensions ranging from 0.01% (anoxia) to 5%, (ii) hypoxia can be chronic, acute, or cycling,
all with differential effects on tumor cells, and (iii) low oxygen tension often occurs in tumor
cells as a result of several processes, for example, poor angiogenesis and increased oxygen
consumption. Dhani et al.49 accordingly report that hypoxia drives a complex compensatory
response in cancer cells (and also in endothelial cells) leading to continued cell survival and
induces genomic changes resulting in selection of hypoxia-adapted cells with the propensity to
invade locally, metastasize, and recur following surgery or radiotherapy. Along the same lines,
Paolicchi et al.50 state that the hypoxic tumor microenvironment promotes metabolic changes,
oncogene activation, epithelial to mesenchymal transition, and resistance to chemo- and radio-
therapy, all of which are hallmarks of aggressive tumor behavior. All of these characteristics are
orchestrated through the activation of the hypoxia-inducible factor 1 alpha (HIF1A), which is
an independent marker of poor prognosis.50,51 Accumulating evidence in recent years suggests
that hypoxia inducible factor 2 (HIF-2) also contributes to chemo- and radio-resistance in solid
tumors.52
In a recent review, Parks et al.53 report that hypoxia promotes tumor growth by controlling
nutrient import and acidic metabolite export. Eales et al.54 state that hypoxic tumor areas
usually contain some of the most malignant cells in a given cancer. Liang et al.51 also state that
the development of cancer therapies that target hypoxia is of vital importance and that one such
targeting strategy is the design of hypoxia-activated prodrugs, which release chemotherapeutic
agents within hypoxic tumor regions. This targeting strategy is accomplished by attaching a
hypoxia-activated trigger to a chemotherapeutic agent such that, under oxygen-poor conditions,
the agent (effector) is released into the tumor, while remaining intact in normal tissue leaving
nonhypoxic cells unaffected.
5. Resistance to Proapoptotic Stimuli
Apoptosis-related signaling pathways have been extensively reviewed by Galluzzi et al.55–57
As stated by Simpson et al.,58 the ability of a cell to survive in an anchorage-independent
manner is a critical step in the development of metastatic potential. Such cells must be able to
overcome anoikis, which is a type of cell death related to apoptosis and results from the loss
of contact with neighboring cells or extracellular matrix.58,59 Portt et al.59 reviewed the various
molecular signaling pathways by which cancer cells evade apoptosis.59 These pathways involve,
among others, activation or upregulation of mitogenic signaling pathways (Erk1/2, Akt, etc.),
inactivation, or downregulation of certain proapoptotic pathways (Fas receptor, Bax, etc.), and
the up-regulation of a number of antiapoptotic genes (Bcl-2, cFLIP, etc.). Portt et al.59 report
that these signaling pathways leading to antiapoptotic phenotypes are activated in response to
not only cytotoxic and proapoptotic insults, but also stressful environment such as hypoxia.
Speirs et al.60 state that an alternative approach to overcome the resistance of cancer cells
to cytotoxic proapoptotic stimuli is to induce cell death pathways that are mechanistically
distinct from apoptosis. These authors accordingly reviewed drugs that induce autophagic cell
death or necrosis in cancer cells.60 However, whether inducing autophagy is beneficial or detri-
mental for cancer cells still remains an actual subject of debate that was recently reviewed
by Belaid et al.61 Indeed, inhibiting (as opposed to inducing) autophagy in cancer cells also
seems to be a promising approach to combat cancers associated with dismal prognoses.62–64
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Furthermore, in addition to apoptosis, autophagy, and necrosis, there are multiple other
cell death pathways that have been reviewed by Galluzzi et al.55–57 Some examples include
necroptosis, mitotic catastrophe, senescence, lysosomal membrane permeabilization, oncosis,
parthanatos, pyroptosis, ferroptosis, and autosis.55–57 We recently reviewed compounds that
are able to induce these various death mechanisms in cancer cells.65 For example, lysosomal
inhibition could emerge as a new therapeutic strategy to overcome drug resistance in cancer.66
Lysosomes aremembrane-bound intracellular organelles that receivemacromolecules delivered
by endocytosis, phagocytosis, and autophagy for degradation and recycling. Later in the review
in Section 4.C, we describe a mollusk-derived compound (belonging to the chemical family of
kahalalides) that has reached clinical trials in oncology and that targets lysosomes inmelanoma
cells displaying marked resistance to apoptosis-related cytotoxic insults.67
GBMis the deadliest type of cancer characterizedbypronounced resistance toproapoptotic
stimuli.68 The only chemotherapeutic drug that leads to real but still limited beneficial effects
for GBM patients is the 30-year-old cytotoxic drug temozolomide.19,69 Much effort has been
applied to discoveringways to kill apoptosis-resistantGBMcells by activating nonapoptotic cell
death signaling pathways, such as paraptosis70–72 or methuosis,73 but none of these attempts
have yet successfully translated into effective treatments for GBM patients. Methuosis is a
nonapoptotic cell death type associated with vacuolization of macropinosome and endosome
compartments.74 Paraptosis is a caspase-independent cell death type.65,75 Lee et al.76 recently
reviewed the natural products capable of inducing paraptosis in cancer cells.
6. Tumor Metastasis
Metastases are resistant to conventional therapies and remain the major cause of death from
cancer.77 Indeed, a great majority of cancer patients (90%) die from tumor metastases78,79
because metastatic cancers are resistant to almost any type of currently available treatment.
Belaid et al.61 accordingly state that the survival rates of patients with metastatic or recurrent
cancers have remained virtually unchanged in the past 30 years.
The metastatic process is characterized by a complex series of interactions between cancer
cells that detach from the primary cancer site, known as circulating cancer cells, and tissue
microenvironment.80 As was discussed in a previous section, circulating cancer cells must
escape anoikis, and thus resist apoptosis, to be able to form secondary cancer sites (metastases).
Of interest, less than 0.01% of circulating cancer cells will succeed in forming metastases81 and
initiating cell growth in secondary organs is the most challenging step in this process.82 While
some cancer types are capable of forming metastases in virtually every tissue in the body, the
most frequent target organs of metastasis are bone, brain, liver, and lung.80 The site preference
is described by the “seed” (cancer cells) and “soil” (the tumor microenvironment) theory
proposed more than a century ago by Stephen Paget,83 which has been validated by extensive
experimental as well as clinical data.80 Part of the seed and soil theory is explained by multiple
tumor–stromal interactions (which however represent only part of the tumormicroenvironment
as explained in the next section) that influence the preference for metastatic spread toward a
given organ.80 Fidler and Kripke77 report that targeting these interactions, in addition to the
cancer cells themselves, can produce synergistic therapeutic effects against existing metastases.
However, Pienta et al.84 state that describing metastasis in terms of a simple one-way migration
of cells from primary to target organs is insufficient to cover the nuances of cancer spread.
Pienta et al.84 thus raise the question of whether cancer cells escape the confinement of their
original habitat in the primary tumor or are they forced out by ecological changes in their
home niche? These authors consequently propose an innovative concept of “diaspora,” which
is a term used by social scientists to describe the scattering of people away from an established
homeland.84 They argue that invoking the ecological and population science concepts can help
understand the biology of tumorigenesis and metastasis, and inspire new ideas for therapy.84
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Another problem linked to metastases is the capability of metastatic cancer cell to
evade therapies by entering dormancy and resuming proliferation years after primary can-
cer treatment.85 Ghajar,86 thus, advocates directing therapies toward the niches that harbor
dormant disseminated tumor cells to sensitize them to cytotoxic agents.
Tumor-associated immune cells also play an important role in the promotion of tumor
metastasis. Indeed, as discussed by Smith and Kang,87 inflammation and infiltration of the
tumor tissue by host immune cells, such as tumor-associated macrophages, myeloid-derived
suppressor cells, and regulatory T cells, have been shown to support tumor growth, invasion,
and metastasis. Smith and Kang87 further describe that each step of tumor development, from
initiation through metastatic spread, is promoted by the communication between tumor and
immune cells via the secretion of cytokines, growth factors, and proteases that remodel the
tumor microenvironment.
7. Tumor Microenvironment
Berns and Pandolfi88 emphasize the major role played by stromal cells in the development of
a cancer, citing the example of pancreatic cancer in which stromal cells and their deposited
matrices can make up to 90% of the tumor mass. Cancer-associated fibroblasts actively interact
with cancer cells and form a myofibroblastic microenvironment that promotes cancer growth
and survival and supports malignancy.89 It appears that specific oncogenes induce cancer-
associated fibroblast phenotype.45 Berns and Pandolfi88 report that stromal components might
contribute to drug resistance by creating a physical barrier limiting drug access, secreting
growth-promoting or antiapoptotic factors, providing niches for CSCs, or by mediating im-
munosuppression. These authors accordingly argue that combining treatments that degrade
the tumor stroma with immunomodulation could be effective given the remarkable success of
immunomodulation in a number of tumors and the notion that the tumor microenvironment
plays an important role in immune suppression.88
Another crucial point in cancer biology is the notion of cancer cell fueling by noncancer
cells. For example, autophagic senescent fibroblasts metabolically promote tumor growth and
metastasis by paracrine production of high-energymitochondrial fuels.90 Migration stimulating
factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor
growth.91 Sotgia et al.92 thus state that asmetabolic symbiosis promotes drug resistance andmay
represent an escape mechanism during antiangiogenic therapy, new drugs targeting metabolic
symbiosis may also be effective in cancer patients with recurrent and advanced metastatic
diseases.
Tabassum and Polyak93 compare tumorigenesis to a village. These authors indeed re-
port that there is growing evidence that cancer cells behave as communities and different
cancer subclones manifest cooperative behavior that can influence tumor progression.93 It
is in this context that the notion of “cancer cell cannibalism” should also be evoked. Ho-
motypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes
metastasis in pancreatic cancer.94 On the other hand, cancer cell cannibalism also leads to
increasing levels of aneuploidy in cancer cells, a cell behavior that could promote tumor
progression.95
Another important component of tumor microenvironment is the tumor vasculature
network. Indeed, as emphasized by Blazejczyk et al.,96 endothelial cells accompany the
malignant cancer cells at almost every stage of the metastatic process. This includes in-
filtration of tumor cells into the neighboring tissue, transmigration through endothelium
(intravasation), survival in the blood stream, and extravasation followed by colonization
of the target organ. The concept of antiangiogenic therapies in oncology raised great
hopes after the pioneering articles by Folkman in the early 1970s.97,98 However, 45 years
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Figure 1. Illustration of selected mollusks under review. (A) Aplysia dactylomela. (B) Aplysia punctata. (C)
Bursatella leachii. (D) Dolabella auricularia. (E) Elysia subornata. (F) Glossodoris quadricolor.(G) Hexabranchus
sanguineus. (H) Jorunna funebris. (I) Onchidium sp. 2. (J) Peltodoris atromaculata. (K) Phidiana militaris. (L)
Phyllidia coelestis. Table I provides taxonomical, geographical, and ecological information about these mollusks,
whose pictures have been taken by one of us.
later, the antiangiogenic therapies have not led to improved clinical outcomes, especially
of cancers associated with dismal prognoses.99 In addition, once cancers develop resis-
tance to antiangiogenic therapy, they may become more invasive or lead to the metastatic
disease.99,100 Rapisarda and Mellilo99 accordingly discuss several studies, which indicate
that inhibitors of vascular endothelial growth factor (VEGF) (and its receptors) can pro-
mote an invasive metastatic switch, in part by creating an increasingly hypoxic tumor
microenvironment.
For further information on the role of tumor microenvironment in supporting cancer
development, the reader is referred to the recent review articles on this topic.101,102 The above
discussion of the tumor microenvironment playing a big role in supporting tumor progression
can lead to a great deal of pessimism for the development of successful therapies. However, it is
important to mention that recently two marine-derived compounds that efficiently combat not
only cancer cells but also the tumor microenvironment, plitidepsin (aplidin), and trabectedin
(Yondelis R©) reached late-stage clinical trials in oncology.103,104
Due to the success of plitidepsin and trabectedin, anticancer agents targeting tumor mi-
croenvironment are actively searched. In marine environment, sessile organisms, especially
sponges, make use of bioactive metabolites to prevent the growth of competitors and foulers,
and to deter predators from feeding.105–108 Although such “chemical warfare” frequently repre-
sents the main defensive strategy of sessile marine invertebrates, slow moving marine mollusks,
including species mentioned in the current review (see Fig. 1 in Section 4.A), are also able to
sequester and reuse the chemical weapons from their prey, especially sponges and cnidarians,
upon which they feed. In a sense, marine mollusks can thus become effective probes for the
selection of bioactive metabolites that evolved in different groups of marine organisms with
possible multitargeted effects on predators and competitors. Even though we are still far from
having identified the molecular mechanisms behind the natural function of the metabolites
from mollusks, it is reasonable to expect that they can interact with more than one molecular
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target with both critical ecological and pharmacological interest, possibly contributing to the
generation of an “antitumor microenvironment.” In other words, the compounds that inhibit
the growth of competitors in marine environment can also affect the growth and evolution of
cancerous cells in the tumor microenvironment as has been showcased with plitidepsin and
trabectedin.
2. WHAT IS A “PROMISING ANTICANCER AGENT?”
The initial steps in anticancer drug discovery utilizing natural sources (plants, fungi, marine
invertebrates) are conducted by chemists or biologists who are neither oncologists nor physi-
cians. After having read hundreds of articles that have led to the writing of the present review,
it became obvious to us that the term “promising anticancer agent” has different meanings
depending on whether it is used by fundamental (chemists and cell biologists) or more applied
researchers (pharmacologists and oncologists). The literature is replete with the use of this term
by the fundamental researchers, who provide cancer cell killing data as the only basis for their
judgment.
To label a particular compound as promising based on cytotoxicity data alone is to forget
that a cancer in a patient is much more complex than a few isolated cancer cells in a plastic
flask, growing alone outside of tumor microenvironment, and without the possibility to metas-
tasize. This is, therefore, the reason why in the Introduction section we summarized the major
characteristics of cancer cell biology and microenvironment representing a crucial obstacle
to successful cancer treatment.109,113 The biological characteristics that we utilize to label an
anticancer compound as promising are described next.
A. In Vitro Activity
1. Antiproliferative Activity
Antiproliferative effects are most commonly expressed as IC50 or GI50 indexes (used inter-
changeably), representing a compound’s concentration that reduces the growth of a given cell
population (normal or cancerous) in vitro by 50% as compared to the (untreated) control con-
dition. GI50 values are generally calculated after having cultured the cell population of interest
for 48 to 72 hr in the presence (or absence) of the compound of interest. This is commonly
done with a colorimetric assay that compares the optical densities (ODs) of a treated cell
population to the ODs of a control condition (untreated cells) arbitrarily scaled at 100%. The
sole GI50 value obtained by means of such a colorimetric assay (e.g., the popular MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay) does not represent actual
cytotoxic effects, a mistake that is unfortunately so often reported in the literature, but rather
only provides relative global growth inhibition information. Indeed, a colorimetric assay does
not differentiate cell killing (cytotoxic effects), the inhibition of cell proliferation (cytostatic ef-
fects), cell detachment (anti-adhesive effects), or various combinations of these features. Once
the GI50 value has been determined by means of a colorimetric assay for a given compound on
a given cell line, it is mandatory to perform complementary morphological and/or biochemical
analyses in order to determine whether the compound is cytotoxic, cytostatic, antiadhesive, etc.
Galluzzi et al. have comprehensively and regularly reviewed all the assays that are available in
this domain, including those that can define the type of cell death.55–57
TheUSNationalCancer Institute (hereafter referred to as theNCI) established colorimetric
assays involving the analyses of compound-induced growth inhibitory effects in a panel of 60
cancer cell lines belonging to more than ten histopathological types.114 The precise strategy
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developed by the NCI is detailed by Shoemaker.115 The NCI researchers use three parameters
calculated from the colorimetric assays to determine whether a compound is cytotoxic or rather
cytostatic. As mentioned above, an NCI-based GI50 value corresponds to a global growth
decrease by 50% induced by a compound on a given cell line after having cultured the cells
with the drug for 48 hr in comparison to an untreated cancer cell population (control condition
= 100%) grown during the same time.115 An NCI-based LD50 (or LC50) value corresponds
to a global growth decrease by 50% induced by a compound on a given cell line after having
cultured the cells with the drug for 48 hr in comparison to the initial number of cells in the
untreated control condition.115 A total growth inhibition (TGI) value is used to determine the
concentration needed to kill 100% of the treated cells.115 For example, based on the combined
analysis of the NCI-based GI50 and LD50 values, we deduced cytotoxic effects induced by
sphaeropsidin A, a rearranged pimarane diterpene of fungal origin, in various cancer cell
lines.116
Simple morphological analyses, such as those performed with phase-contrast microscopy,
can be quite useful in interpreting the data obtained with a colorimetric antiproliferative assay
and, specifically differentiate cytotoxic from cytostatic effects. For example, suchmorphological
analyses confirmed the cytotoxic nature of sphaeropsidin A that was originally deduced based
on the NCI data.116 In contrast, narciclasine, an isocarbostyril isolated from daffodils,117,118
was cytostatic at its GI50 concentration in melanoma cells as was concluded on the basis of
morphological analyses.119
It must also be emphasized that colorimetric assays can lead to false-positive or false-
negative data with respect to certain types of compounds.120 In addition, for some compounds
the growth curves can reach a plateau-phase in certain cancer cell lines.121 In both cases,
morphological analyses can be useful to validate the data generated by a colorimetric assay,
not only in cancer, but also in normal cells.
The GI50 indexes that precisely define the ranges “weakly active,” “active,” and “highly
active” are not unanimously agreed upon in the literature. The instructions for authors of
the Journal of Natural Products define a compound to be inactive if its GI50 value is higher
than 10 μM. The NCI also uses 10 μM as the highest dose for compounds tested in the 60
cell line panel. However, some compounds that work through nonapoptotic mechanisms (e.g.,
inducers of senescence or autophagy) can displayGI50 values higher than 10μM.Thus, we took
these issues into account in comments about the “promise” associated with a given anticancer
compound.
2. Selectivity
The term “selective” is not a synonym for “bioselective” (see Section 2.A.3). A compound is
“selective” when it displays in vitro growth inhibitory selectivity with respect to one or several
histological groups of cancer cell lines out of a larger number of histological cancer types. The
data obtained in the NCI 60 cell line panel are most useful in determining selectivity.114,115
For example, using the NCI data we found that sphaeropsidin A displays in vitro selectivity
against melanoma and kidney cancer cell lines.116 This type of information is very important
in the design of further in vivo experiments, including, for example, the use of nanomedicine
approaches to target a specific organ in which a cancer develops.122–124
3. Bioselectivity
The term “bioselective” is used to refer to a compound that displays differential growth in-
hibitory effects between normal and cancer cell lines. In the current review, we label a compound
as “bioselective” if it displays a GI50 ratio of higher than 3 between normal and cancer cells,
which is not highly discriminant but acknowledges the efforts applied by researchers of a given
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article to perform this kind of analysis. The ratio of 3 is also indicative of the possibility to
make more bioselective derivatives of the compound of interest.
4. Characterization of the Mechanism(s) of Action
The NCI researchers have tested so far 800,000 compounds and developed an algorithm
(the COMPARE software)115 that can assist in identifying a compound’s mode of action. The
COMPARE software compares the shapes of 60 growth inhibitory curves (one per each of
the 60 cancer cell lines) of each of the 800,000 compounds available in the NCI database
to the growth curves determined for a compound of interest.115 Each growth inhibitory curve
is determined using five concentrations ranging from 0.001 to 10 μM for a given compound.
The COMPARE software thus provides a statistical probability value that the compound of
interest acts as, for example, a tubulin inhibitor, protein synthesis inhibitor, or a topoisomerase
II poison. If the statistical probability provided by the COMPARE software is weak (< 0.05),
it is potentially indicative of a novel mechanism of action. For example, the COMPARE
tool assisted us in identifying a novel compound of interest (a novel trisubstituted harmine
derivative) as being a potential protein synthesis inhibitor,125 a fact that was later validated at
the biochemical level. The NCI contributed to the characterization of the anticancer activity
and/or the characterization of the mechanism(s) of action of major anticancer drugs that are
listed in the review by Shoemaker.115 The NCI 60 cell line panel also represents a powerful tool
for studying the effects of a given compound at the level of mutations,126 transcript and protein
expression profiles,127 microRNA expression profiles,128 and global proteome analysis.129
In the Introduction section, we emphasized why proapoptotic cytotoxic agents are not
promising in combating cancers associated with dismal prognoses. Thus, we do not label as
“promising” an anticancer compound that kills cancer cells (in vitro) through proapoptotic
mechanisms, with no in vivo demonstration of activity. We summed up in the Introduction
the extraordinary complexity of the metastatic biological process. It is at first glance difficult
to appreciate in vitro the potential antimetastatic effects of compounds that are evaluated in
cancer cells that are grown isolated, without cancer-associated cells, in a 2D environment. We,
nevertheless, identify promise in compounds displaying in vitro-specific antimetastatic prop-
erties such as effects on cancer cell adhesion, motility, migration, or invasion. We highlight
compounds displaying effects on cell adhesion at the level of cell–cell and/or cell–extracellular
matrix interactions, or affecting the adhesive machinery of cancer cells including, for example,
the focal adhesion kinase (FAK)130 and beta-1 integrins.131 We also consider that a compound
displays “in vitro antimetastatic effects” if it decreases cancer cell migration132 and/or if it
targets cytoskeleton or cytoskeleton components such as actin or tubulin.132 Finally, we re-
gard a compound as able to affect cell invasiveness if it inhibits proteases implicated in the
metastatic cascade, such as cysteine cathepsines,133 and/or if it inhibits migration in transwell
migration assays. We highlighted in the Introduction the importance of the MDR phenotype
in the resistance of cancer cells to chemotherapeutics, especially in relation to natural cytotoxic
compounds. Thus, we emphasize compounds that have shown ability to bypassMDRprocesses.
Lastly, we also highlighted in the Introduction section the major roles displayed by hypoxia
and CSCs in cancer chemoresistance. We describe promising compounds that can be triggered
by hypoxia or that have been shown to affect CSCs.133,144
B. In Vivo Activity
As emphasized by Cekanova and Rathore,145 cancer is the term used to describe over 100
diseases that share several common hallmarks. There are in vivo models for any type of
cancer, which can be studied in a large variety of species ranging from Drosophila flies146,147
to zebrafish,147 and rodents148–152 to companion animals such as cats and dogs.145,153,154
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However, most in vivo preclinical models involve rodents (mostly mice) and generally belong to
two groups, cancers developing in immunocompetent rodents and human cancers xenografted
in immunocompromised (“nude”) or immunodeficient (SCID) rodents. Cancers developing in
immunocompetent mice are obtained by grafting procedures from preexisting solid tumors or
cancer cell lines, genetic manipulations, or chemically inducing cancer, among other strategies.
Cancers developing in immunocompromised or immunodeficient mice are xenografted into
rodents from preexisting solid tumors, cancer cell lines, or cancer cells directly obtained from
patients.
There are comprehensive reviews for each type of organ-specific cancer that analyze the
advantages and disadvantages of eachmodel. In the following sections, we highlight compounds
that have been evaluated for therapeutic efficacy in vivo in various preclinical models of cancer
and in clinical trials.
3. MARINE NATURAL PRODUCTS AS SOURCES OF NEW ANTICANCER DRUGS
Natural products, their potency, selectivity, and mechanisms of action have evolved in nature
as critical adaptations, serving as protection from predators, inhibiting competitors, parasites,
and pathogens, and influencing reproductive and alimentary behavior. Natural selection is thus
the reason behind their importance as drug candidates.155 Even though a detailed discussion
of the possible natural functions of the bioactive metabolites is beyond the scope of this
review, it is worth noting that chemoecological role of natural products is only available for a
limited number of natural compounds. Chemical ecology, the discipline focusing on chemically
mediated ecological interactions between organisms, is quite new.156,157 Instead, the traditional
man-centered perspective on natural products, which is focused on potential medicines, has
roots in ancient history and still being a key driver of natural product research.
However, over the past few decades the role of natural products in drug discovery has
suffered from several changes. After a boost over the last half of the 20th century, the
field experienced a sharp decline as the pharmaceutical industry practically abandoned nat-
ural product research in the mid-1990s and shifted the focus toward building massive com-
pound libraries via combinatorial chemistry.158–160 Still, against all expectations, in the last
25 years, 70% of all approved drugs have been natural products or their derivatives, while
only a few de novo combinatorial compounds have been approved as drugs.160–163 A spe-
cial issue on Natural Product-Based Drug Discovery was published in 2016 in Medicinal
Research Reviews. In addition, reviews published on a regular basis by David J. Newman
and Gordon M. Cragg are an excellent source of information on product-based cancer drug
discovery.161,164–168
In the genomic era, with the advent of a series of novel technologies that speed up the
rates of natural product discovery and assist in identifying novel mechanisms of action, there
has been a steady reemergence of natural product-based drug discovery as reviewed by Harvey
et al.169 Some of these technologies involve a recapitulation of tumor ecosystems in 3D culture
models134 with the possibility to apply quantitative high-throughput screening,135 patient-
oriented screening,141,142 the use of cut tissue slices,144 or “organs-on-chips” approaches,170
among others.
Traditionally, natural product-based drug discovery mainly concerned the study of com-
pounds isolated from terrestrial organisms, including bacteria, fungi, and especially higher
terrestrial plants (Trachaeophyta), many of which employ some form of chemical defense to
escape predation by herbivores.168,171–176 In contrast, the history of marine natural products in
the context of anticancer drug discovery is relatively young. Oceans and seas constitute 75% of
the Earth surface in which nearly one million multicellular (plants and animals) and one billion
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unicellular (distributed under 100 different phyla) species live. Oceans and seas have already
yielded 26,000 active compounds.177 Blunt et al.177 report that these 26,000 compounds
belong to 9000 collections obtained worldwide since 1965.
Similar to their terrestrial counterparts, marine organisms have evolved to produce bioac-
tive compounds to adapt to environmental conditions and especially to deter feeding by preda-
tors (defensive allomones). Mitsiades et al.178 argued that compounds derived from marine
organism may have evolved to be more potent than similar compounds from the above-water
organisms to compensate for the increased diffusion and thus rapidly decreasing protective con-
centration gradient of these compounds under water. However, although such considerations
are certainly appropriate for water-soluble polar compounds, low water solubility of many
bioactive marine natural products, especially terpenes, instead prevents their dilution in the
medium, allowing them to act at high doses during the contact with predators.179 In some
cases lipophilicity may thus be an important feature both in preventing the dilution of defen-
sive chemical weapons in water and making bioactive compounds of interest in pharmacology
capable of permeating lipophilic biomembranes.
The NCI estimates that more than 1% of marine natural products show antitumor
properties as compared to the 0.01% among their terrestrial counterparts.180 The marine-
sourced anticancer and cancer pain control agents that have reached late preclinical and clin-
ical development were recently reviewed by Newman and Cragg.166 Gerwick and Moore110
reported in 2012 that the success rate of discovery from the marine world (for any type
of clinical indication) with seven clinically useful and approved drugs from 22,000 discov-
ered molecular entities (i.e., one drug per 3140 natural products described) is thus approxi-
mately 1.7- to 3.3-fold better than the industry average, which is one in 5000–10,000 tested
compounds.181,185
Skropeta andWei186 reviewed in 2014 (for the period 2009–2013) 188 novel marine natural
products from deep-water (from 50 to >5000 m) marine fauna including bryozoa, chordata,
cnidaria, echinodermata, microorganisms, mollusca, and porifera. They report that 75% of
the compounds they reviewed possess bioactivity, with almost half exhibiting low micromolar
cytotoxicity toward a range of human cancer cell lines. Gerwick and Moore110 also report that
mollusks, sponges, and tunicates are the richest collected sources of clinically useful drugs.
However, they emphasize a lot of evidence showing that the actual producers of the bioactive
substances are associated microorganisms (mainly heterotrophic bacteria and cyanobacteria).
In addition, a trophic transfer of the compounds from sponges to their specialist nudibranch
predators is also described.187–189
The next section covers the anticancer potential of molecules isolated from the phylum
Mollusca describing the in vitro, in vivo preclinical and clinical studies published in the liter-
ature (PubMed and Scopus databases). As emphasized by Molinski et al.,159 drug discovery
from marine natural products has enjoyed a renaissance in the past few years due to the re-
cent marketing of the cancer pain control agent ziconotide (Prialt R©) and the anticancer drug
trabectedin (Yondelis R©).
4. MOLLUSK-DERIVED ANTICANCER AGENTS
Given the controversial theme of the biosynthetic origin of the metabolites isolated from
mollusks, it must be emphasized that in the current review we chose to simply consider the
studied mollusks as the natural sources of the compounds under investigation, and not their
actual producers. Although some of the bioactive compounds under review are produced
by the mollusks themselves, most of them are, in fact, of dietary origin. Noteworthy, the
“mollusk-derived” metabolites that entered or that are in clinical trials are actually produced
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bymicrobes. Consequently, the study of the molluscan chemistry has often resulted in the study
of compounds produced by organisms at lower trophic levels.
A. Mollusks as Natural Product Sources
The phylum Mollusca shows great morphological, ecological, and chemical variability and it
is subdivided in two subphyla, the Auculifera and the Conchifera. The Auculifera, which do
not produce a complete shell, comprise the two classes of the Aplacophora, worm-like in form,
and the Polyplacophora, with a dorsal shell divided into eight valves. The shelled Conchifera
includes five classes: (i) the Monoplacophora with a cap-shaped shell; (ii) the Gastropoda
including snails, slugs, and limpets; (iii) the Cephalopoda including octopuses, cuttlefish, and
squids; (iv) the Bivalvia such as clams, oysters, scallops, and mussels; and (v) the Scaphopoda
with a tubular shell.190 Most of the chemical studies on marine natural products have been
focused on the gastropods, which are traditionally divided in three major groups, the subclasses
Prosobranchia, Pulmonata, and Opisthobranchia,188 and more recently on the bivalves.191
Marine mollusks can be found from tropical seas and temperate waters to Artic-Antarctic
regions, showing different morphologies and occupying a wide range of ecological niches.192
They feed on a wide variety of benthic invertebrates and plants, often accumulating dietary
metabolites from their prey to be reused against their own potential predators. Consequently,
and as emphasized above, the study of the molluscan chemical diversity involves, at least in
part, the exploration of the chemical composition of organisms at lower trophic levels.
Mollusks are also able to accumulate the dietary metabolites in localized anatomical
structures.193,194 This type of defensive strategy, which is particularly common in opistho-
branchs, can be reinforced by the presence of visual aposematic patterns, which can be shared
by groups of similarly colored species that share the cost of the education of predators within
Mu¨llerian mimetic circles.195 Recently, it has been even proposed that a group of nudibranchs
belonging to the family Chromodorididae forms a putative Mu¨llerian mimetic circle based on
a common chemosensory signal, the anticancer macrolide latrunculin A, which is among the
compounds discussed in this review.189 In Table I, we provide taxonomical, geographical, and
ecological information for the mollusks under review and in Figure 1, we illustrate a selection
of these organisms.
If reproducibility is a crucial issue in all sciences, it assumes a critical importance in cancer
research. When the bioactive compounds are difficult or costly to synthesize, the extraction
from natural sources may be the only realistic way to provide sufficient amounts of puri-
fied metabolites for preliminary pharmacological screenings. Consequently, the correct species
classification and information about the collection sites becomes of utmost importance. Even
appropriate taxonomic and geographic information, however, is not always sufficient. Intraspe-
cific variations in secondary metabolites between individuals of a given species, in fact, are
widely documented in the literature. In addition, given that the taxonomy evolves, sometimes
it is difficult to track the source of a given metabolite in the available chemical literature. The
so-called “chemotaxonomy” adds more confusion to the issue because a secondary metabolite
can be of dietary origin, produced by symbionts, or de novo biosynthesized. This generate a sort
of “labyrinth” from which we could get out only by providing, in the future, more information
about the origin of the metabolites, more biosynthetic studies, more accurate GPS data of the
sampling locations, and more complete information about the cases of synonymy and possible
misidentification.
The current review highlights the diversity of chemical structures, mechanisms of action,
andmost importantly the assessment of “promise” ofmollusk-derivedmetabolites as anticancer
agents. We include, as mollusk-derived metabolites, compounds that were originally identified
in mollusks. However, since the initial discovery of certain metabolites with anticancer effects
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Figure 2. Chemical structures of dolastatin 10 (1a), soblidotin (TZT-1027; 1b), and symplostatin 1 (1c).
in a given mollusk, it has been demonstrated in certain cases that these compounds are not
biosynthesized by the mollusk but instead are of dietary origin. We thus provide in Table II all
the compounds under review (alphabetically listed) that were initially discovered in mollusks
and we also report the possible actual producer(s) of the compounds of interest when such
information is available in the literature.
B. Dolastatins
We describe below the cyanobacterial metabolites of the dolastatin type. However, it must be
recalled that these types of compounds did not successfully complete clinical trials, usually
exiting trials at or before the Phase II level. Thus, though we detail below the use of agents
derived from dolastatins as potential anticancer agents, it should be noted that most of the
Phase I trials did not proceed any further. Therefore, dolastatins can no longer be labeled as
“promising anticancer drugs.”
Dolastatins (1a-14b; Figs. 2–6) embody a large family of active compounds originally
isolated from Dolabella auricularia (Anaspidea mollusk, Table I; Fig. 1D). From the chemical
point of view, dolastatins showhigh structural heterogeneity including linear and cyclic peptides,
depsipeptides, peptides containing the thiazole and oxazole heterocycles, and macrolides. The
low concentrations of dolastatins found in sea hares suggested a dietary origin and this was
subsequently confirmed by direct isolation of dolastatin 10 from field collections of the marine
cyanobacterium Symploca.196 Also, it has been confirmed for a number of other dolastatins
that they are not produced by sea hares,197 but ingested and sequestered from the dietary
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Figure 3. Chemical structures of brentuximab vedotin (SGN-35; Adcetris R©; 1d), dolastatin 15 (2a), tasidotin
(ILX-65; 2b), dolastatin 1 (3), and dolastatin 3 (4). MAB in structure 1d represents the monoclonal antibody
portion of this ADC.
cyanobacteria. In some cases, the true producers of dolastatins have been demonstrated to be
cyanobacteria of genus Symploca (Table II) recently revised into the new genus Caldora and
species penicillata,198 as well as Lyngbya.
As reported by Pettit et al.,199 the genus Dolabella has interesting history. The Roman
natural scientist Pliny the Elder comprehensively studied and then described (60 A.D.) a
potent Indian Ocean sea hare of the genus Dolabella. The Romans named the Mollusca of
the family Aplysiidae as “sea hare” due to the similarity between the ears of a hare and the
auriculate tentacles of these gastropods.199 Extracts from the Dolabella sea hare were already
known for their toxic properties during the reign of Nero.199 Nicander (150 A.D.) recognized
the possibility of usingDolabella extracts to treat certain diseases.199 Pettit et al.199 thus argued
that the dolastatin family of compounds they discovered (see below) most probably correspond
to the potentD. auricularia constituents recognized by the above-named Romans. Among these
largely diverse compounds, the linear peptides dolastatin 10 and 15 show the most remarkable
picomolar GI50 values in most in vitro cancer growth inhibition studies.200
Dolastatin 10 (1a; Fig. 2; Table II) was first isolated from D. auricularia collected from
the Indian Ocean201 and then discovered (with its methyl derivative, symplostatin 1) in the
cyanobacterium Symploca hydnoides.196 Dolastatin 10 is a linear pentapeptide with four of
residues being structurally unique: dolavaline (Dov), dolaisoleuine (Dil), dolaproine (Dap), and
dolaphenine (Doe), in addition to valine (Fig. 2). Its absolute configuration was established by
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Figure 4. Chemical structures of dolastatin 11 (5), dolastatin 12 (6), dolastatin 13 (7), and dolastatin 14 (8).
synthesis by Pettit et al.202 Singh et al.203 comprehensively reviewed the historical development
of dolastatin 10. Briefly, it entered Phase I clinical trials in the early 1990s under the auspices of
the NCI. Then, several Phase II clinical studies (advanced and metastatic soft tissue sarcoma,
advanced hepatobiliary cancers, pancreatic cancers, among others) did not reveal the efficacy
of dolastatin 10 (1a) as a single anticancer agent due to dose-limiting side effects, such as
neuropathy.203
Singh et al.203 explained that although clinical trial results with dolastatin 10 were discour-
aging, these as well as preclinical studies offered the basis for structure–activity relationship
(SAR) analyses and have led to the discovery of soblidotin (TZT-1027, 1b; Fig. 2), a synthetic
analogue of dolastatin 10,203,204 in which the thiazolemoiety of the dolapheninewas replaced by
phenylalanine methyl ester. The in vitro growth inhibitory effects of soblidotin decline depend-
ing on the amount of P-gp expressed in cancer cells.205 Soblidotin displayed in vivo anticancer
activity in several models including the murine P388 leukemia, Colon26 colon cancer, Lewis
Lung carcinoma, B16 melanoma and M5076 sarcoma models as well as human MX-1 breast
cancer, and LX-1 and SBC-3 SCLC xenografts.205 Soblidotin entered several Phase II clinical
trials (advanced and metastatic soft tissue sarcomas, NSCLCs, among others) but it was also
found ineffective as a single agent and its clinical development was no longer pursued.203
The GI50 index of dolastatin 10 in the NCI 60 cell-line panel is0.2 nM and a COMPARE
analysis with a cut-off correlation at p = 0.7 is negative in the standard agent dataset. This
agent is not able to overcome the MDR phenotype mediated by the P-glycoprotein (P-gp)
in cancer cells206 as is also the case with respect to its analogues soblidotin205 and symplo-
statin 1 (1c; Fig. 2).207 Dolastatin 10 induces proapoptotic stimuli in cancer cells208,209 as do
soblidotin205,210 and symplostatin 1.207 Dolastatin 10 was rapidly identified as an inhibitor of
tubulin polymerization.211 In addition to the inhibition of tubulin polymerization, it inhibits
tubulin-dependent GTP hydrolysis and the binding of vinblastine, maytansine, and vincristine
to tubulin, although its binding site on tubulin is different from that of the vinca alkaloids.210
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Figure 5. Chemical structures of dolastatin 16 (9), dolastatin 17 (10), dolastatin 18 (11), dolastatin D (12),
dolastatin G (13a), and nordolastatin G (13b).
The tubulin-binding sites of colchicine, taxol, vinblastine, rhizoxin F, and maytansine are dis-
cussed by Prota et al.212 and in the commentary by Field et al.213
Dolastatin 10 displays in vivo anticancer activity in various models, including, for exam-
ple, MDR diffuse large cell lymphoma WSU-DLCL2,214 SCLC NCI-H446215, and ovarian
carcinoma216 xenografts. Dolastatin 10 also displayed anticancer activity in various cancer
models at the NCI: mouse P388 and L1210 leukemia, B16 melanoma and M5076 sarcoma as
well as human LOX melanoma, and MX-1 breast cancer xenografts.
In addition to soblidotin, the modification of C-terminus of dolastatin 10 yielded a series
of analogs called auristatins.217 However, these were also ineffective in clinical trials.200 An
important discovery was made by Miyazaki et al.,218 who found that the removal of one
N-methyl group of dolavaline at the N-terminus of dolastatin 10 gives an analog showing only
slightly attenuated potency. With this secondary amine at their N-terminus free, the auristatins
became suitable for attachment of a linker to facilitate its conjugation tomonoclonal antibodies,
leading to the generation of highly potent and efficacious antibody drug conjugates (ADCs).
This led, for example, to the FDA-approved ADC brentuximab vedotin (SGN-35, Adcetris R©;
1d; Fig. 3).219 Vedotin is monomethyl auristatin E chemically conjugated to the chimeric anti-
CD30 antibody.220 It was approved for the treatment of relapsed Hodgkin lymphoma and
systemic anaplastic large-cell lymphoma.221 Over 30 ADCs in clinical trials currently employ
auristatins as payloads. The reader is referred to recent reviews on this subject.166,200,219,222
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Figure 6. Chemical structures of dolastatin H (14a), isodolastatin H (14b), kahalalide F (15a), and elipsidepsin
(15b).
After Pettit et al. published the structure of dolastatin 15 (2a; Fig. 3; Table II), also
isolated fromD. auricularia,223 several groups developed its total synthesis.224,225 The supply of
synthetic dolastatin 15 has allowed its biological evaluation. Dolastatin 15 also interacts with
tubulin and may bind in the vinca domain of tubulin, presumably in the same site as dolastatin
10.226 It induces a loss of tension across the kinetochore pairs due to the disruption of normal
microtubule assembly dynamics.227 Beckwith et al.228 reported that dolastatin 10 and 15 display
in vitro antiproliferative activities that are three to four orders of magnitude more potent than
vincristine, a clinically used antiproliferative agent, while dolastatin 15’s NCI-based GI50 is
about ten times higher than that of dolastatin 10 (2 vs. 0.2 nM). Dolastatin 15 was also slightly
inferior in terms of in vivo anticancer activity in a human ovarian carcinoma xenografted
model.216 Dolastatin 15 is a classical inducer of apoptosis in cancer cells and thus behaves as
a conventional proapoptotic cytotoxic agent.229,230 Furthermore, it is not able to overcome the
MDR phenotype mediated by the P-glycoprotein (P-gp) in cancer cells.216
Like for dolastatin 10, a series of SAR studies have been undertaken with the focus on
structural and stereochemical modification at the C terminus (Hiva-Dpy).217 These studies led
to the discovery of tasidotin, which was advanced to clinical trials. Tasidotin (ILX-651; 2b; Fig.
3) is a peptide analog of dolastatin 15 in which the carboxyl-terminal ester group is replaced
by the tert-butyl amide.231 Tasidotin, which is orally active, reduces the shortening rate, the
switching frequency from growth to shortening (catastrophe frequency), and the fraction of
time the microtubules grow.232 Tasidotin is a proapoptotic cytotoxic compound233 and it is also
a P-gp substrate234 as all the other dolastatins. It showed promising in vivo anticancer activity
in preclinical models of pediatric sarcomas,233 LOX melanoma xenografts,234 and xenograft
models of breast cancer, ovarian cancer, prostate cancer, and colon cancer as reported in the
Medicinal Research Reviews DOI 10.1002/med
MARINE MOLLUSK-DERIVED AGENTS WITH ANTIPROLIFERATIVE ACTIVITY  729
ILX-651 investigators brochure (Genzyme Corp., 2004) cited by Garg et al.,233 but not in H460
NSCLC xenografts.234 Tasidotin was also efficient in vivo in murine P388 leukemia model.233
But as for soblidotin, the clinical development of tasidotin was not pursued beyond Phase II
clinical trials because of lack of efficacy.
As mentioned above, all dolastatins seem to be proapoptotic agents unable to circumvent
the MDR phenotype in cancer cells and they all displayed poor anticancer activity in Phase II
clinical trials, leading to the discontinuation of their clinical evaluation.203
In 1981, Pettit et al.199 claimed that dolastatin 1 (3; Fig. 3; Table II), which was isolated
from D. auricularia, represented by that time the most potent anticancer agent discovered with
an 88% life extension (at a dose of 11 μg/kg) in the murine P388 lymphocytic leukemia model,
and a curative rate (33% at a dose of2 μg/kg) in the murine B16 melanoma model. The NCI
60 cell-line panel had not been established yet at that time.115
Dolastatin 3 (4; Fig. 3; Table II), a cyclic peptide containing two thiazole rings, was isolated
from a Japanese specimen ofD. auricularia (Fig. 1D) and displayed the GI50 of<1 μM in P388
murine leukemia cells.235 Its full structure was confirmed by synthesis some years later.236 This
compound was also isolated from a Palauan collection of Lyngbya majuscula.237 Dolastatin 3
induced in vivo a 78% life extension in the murine P388 lymphocytic leukemia model and a 52%
life extension in murine colon carcinoma 38.237
Dolastatin 11238 (5; Fig. 4; Table II), dolastatin 12238 (6; Fig. 4; Table II), dolastatin
13239 (7; Fig. 4; Table II), and dolastatin 14240 (8; Fig. 4; Table II) are depsipeptides isolated
from D. auricularia. Dolastatin 12 was also isolated from L. majuscula/Schizothrix calcicola
cyanobacterial assemblages (Table II).241 Dolastatin 11’s mean GI50 was0.07 μM in the NCI
60 cell line panel and the COMPARE analysis with a cut-off correlation at p= 0.7 was negative
in the standard agent dataset. Dolastatin 12’s GI50 values ranged from 1 (human NCI-H460
NSCLC) to 30 nM (human SF-295 CNS cancer) when assayed in five cancer cell lines.242
Additionally, its GI50 values in mouse neuro-2a neuroblastoma243 and P388 leukemia238 cells
were 0.1 and >1 μM, respectively. Dolastatin 13’s and 14’s GI50 values were 14 nM239 and
20 nM,240 respectively, in the murine P388 leukemia cell line.
While both dolastatin 10 and 15 affect tubulin as detailed above, dolastatin 11 targets
actin and it displays about threefold higher growth inhibitory effects than the sponge-derived
depsipeptide jasplakinolide.244 Dolastatin 11 does not arrest cancer cells in mitosis, as do
dolastatin 10 and 15, but induces massive rearrangement of the cellular actin filament network
leading to dramatic cytoplasmic retraction and subsequently cell division arrest at the level
of cytokinesis.244 It binds actin at a site distinct from phalloidin,244 which is a toxin from the
mushroom Amanita phalloides245 and one of the best known antiactin compounds.246 Specif-
ically, dolastatin 11 connects two long-pitch strands in F-actin to stabilize microfilaments.247
Tubulin and actin are not only key players in normal and cancer cell division, but also in cancer
cell invasion and metastasis.248
As reported above for dolastatin 11, dolastatin 12 also targets actin microfilaments.241 A
dolastatin 12 analog displayed only marginal or no in vivo anticancer activity against murine
colon adenocarcinoma 38 and mammary adenocarcinoma 16/C and appeared to be toxic.241
Dolastatin 16 (9; Fig. 5; Table II) is a cyclic depsipeptide containing two new amino
acids, dolamethylleuine, and dolaphenvaline collected from D. auricularia in Papua New
Guinea.249 The X-ray crystal structure of dolastatin 16 and syntheses of the new amino
acid units dolamethylleuine and dolaphenvaline were published later.250 Dolastatin 16 was
also isolated from a Madagascan collection of L. majuscula251 as well as from Symploca cf.
hydnoides collected off Guam.252 Dolastatin 16’s GI50 values were in low nanomolar ranges
when assayed in a mini panel of four human solid cancer cell lines and in five leukemia
cell lines.249 Its mean GI50 in the NCI 60 cell line panel was 0.3 μM and COMPARE
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analyses provided relatively low correlations with dolastatin 10 (p = 0.76) and dolastatin 15 (p
= 0.71).249,253 The total synthesis of dolastatin 16 consisting of 23 stepswas recently achieved.254
Interestingly, Pettit et al.254 report that the synthetic dolastatin 16, while otherwise identical
(by X-ray crystal structure and spectral characteristics) with the natural product, did not re-
produce the nanomolar cancer cell growth inhibition displayed by the natural isolate. Pettit
et al.254 reported that presumably this result can be attributed to the conformation(s) of the
synthetic dolastatin 16 or to a chemically undetected component isolated with the natural
product.
Additional dolastatins that have been isolated from D. auricularia are dolastatin 17255 (10;
Fig. 5), collected in Papua New Guinea specimens; dolastatin 18256 (11, Fig. 5), collected in
Indian Ocean specimens; as well as dolastatin D257 (12; Fig. 5), dolastatin G258 (13a; Fig. 5),
nordolastatin G258 (13b; Fig. 5), dolastatin H259 (14a; Fig. 6) and isodolastatin H259 (14b; Fig.
6) found in Japanese specimens.
Dolastatin 17 (10) is a cyclodepsipeptide with a novel acetylenic β-amino acid named
dolayne (Doy), similar to that found in onchidin260 (discussed in Section 4.D.2). Dolastatin 17’s
GI50 values were in submicromolar ranges in the four cancer cell lines in which it was assayed.255
Dolastatin 18 (11) is characterized by the presence of a thiazole ring in its structure. Its GI50
values were in submicromolar ranges in the mouse P388 lymphocytic leukemia and the human
NCI-H460 NSCLC cell lines.256 Dolastatin 19 (57, for structure see Fig. 16), isolated from a
different collection of D. auricularia specimens from the Gulf of California,261 is a macrocyclic
lactone that is strongly related to aurisides as illustrated in Section 4.D.3 (Table II). Dolastatin
19 displays in vitro growth inhibitory activity with GI50 values of1 μM in breast MCF-7 and
colonKM20L2 cancer cells.261 DolastatinD is a cyclic depsipeptide with aGI50 value of4μM
in human HeLaS3 cancer cells.257 Dolastatin G and nordolastatin G are cyclic depsipeptides
with GI50 values of 1 and 5 μM, respectively, in human HeLaS3 cancer cells.258 Dolastatin
H and isodolastatin H, isolated from Western Indian Ocean specimens of D. auricularia, are
linear peptides closely related to dolastatin 10.259 Synthetic dolastatin H displayed a GI50 value
of 2 nM in human HeLaS3 cancer cells.259 Isodolastatin H was evaluated in vivo against murine
P388 leukemia and shown to exhibit antitumor activity that is slightly weaker (41% of life time
extension as compared to control) than that of dolastatin 10 (55% of life time extension as
compared to control).259
C. Kahalalides
Many sacoglossan mollusks feed upon algae from which they acquire biologically active
metabolites. For example, several species ofElysia sequester toxic compounds fromBryopsis.262
In particular Elysia rufescens (Table I), E. grandifolia, and E. ornatawere found to contain dep-
sipeptides called kahalalides present also in Bryopsis, which are known to be responsible for
the deterrent properties of the mollusks.263 Davis et al.264 report that sacoglossan mollusks are
characterized by the ability to sequester functional chloroplasts from their algal diet through
a process called kleptoplasty, enabling them to photosynthesize. These authors provided ex-
perimental evidence showing that a diverse bacterial assemblage is associated with E. rufescens
and its mucus, with secreted mucus harboring higher bacterial richness than entire E. rufescens
samples. Davis et al.264 have thus shown that the most abundant bacterial groups affiliated with
E. rufescens and its mucus areMycoplasma spp. and Vibrio spp., respectively. They accordingly
suggest that kahalalide F, found in E. rufescens (Table I), is possibly of bacterial origin.
Chemically, the size and composition of kahalalides are highly variable, ranging from aC31
tripeptide to a C77 tridecapeptide, and each peptide contains a different fatty acid chain.263
Kahalalide family has reached more than 20 members, of which kahalalide F is the most
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promising anticancer agent as detailed below. Gao and Hamann263 comprehensively reviewed
in 2011 the chemistry and biology of kahalalides.
Kahalalide F (15a; Fig. 6; Table II) is a cyclic peptide connected with an amidic bond to
a short chain fatty acid. It was isolated from the herbivorous sacoglossan mollusk E. rufescens
(Table I) living in the seas near Hawaii, and then from its green algal diet Brysopsis pennata
(Brypsidaceae).262 Before describing its anticancer effects, we would like to draw the reader’s
attention to the following point. Some articles report on oncosis-like effects induced by kaha-
lalide F in cancer cells, while others report on the induction of necrosis-like features. At first
glance, it thus seems that kahalalide F could induce either oncosis or necrosis in cancer cells,
while in fact this is not the case. Indeed, as clearly stated byWeerasinghe and Buja,265 oncosis is
a term that actually relates to a mode of cell injury and cell death, while necrosis relates to a cell
population (tissue) degradation process following cell death. In other terms, necrosis should not
be used to describe a specific death process occurring in single cells. Weerasinghe and Buja265
comprehensively reviewed the oncosis-related characteristics at both morphological and bio-
chemical levels and they define that oncotic cell death involves progressive membrane injury
involving three stages that they detail in their review. These authors thus define oncosis as a
form of cell death accompanied by cellular swelling, organelle swelling, blebbing, and increased
membrane permeability caused by the failure of various ionic pumps in the plasma mem-
brane, with increases in concentrations of cytosolic calcium and rearrangement of cytoskeletal
proteins.265
The fact remains that (i) oncosis shares no common signaling pathways with apoptosis,265
(ii) lysosomal targeting can lead to cell death types other than oncosis,266–268 and (iii) altered
cancerous lysosomes are involved in promoting cancer progression of metastatic disease.267
Inducing oncosis in cancer cells would thus make it possible to overcome the resistance to
proapoptotic stimuli displayed by cancer cells associated with aggressive biological behaviors.65
Sua´rez et al.269 accordingly observed that kahalalide’s F cytotoxicity did not correlate with the
expression level of theMDR1 efflux pump. In fact, Garcı´a-Rocha et al.270 already reported two
decades ago that kahalalide F kills cancer cells via the targeting of lysosomes. Sua´rez et al.269
then reported that kahalalide F induces oncosis in human prostate and breast cancer cells.
Sua´rez et al.269 thus suspected that kahalalide F does not induce apoptosis in cancer cells.
This hypothesis was then experimentally confirmed by Janmaat et al.,271 who observed that
several markers of caspase-dependent apoptosis, such as phosphatidyl-serine externalization,
cytochrome c release, and caspase-3 and poly-(ADP-ribose) polymerase cleavage were negative
after exposure of cancer cells to kahalalide F. Also, inhibitors of caspases or cathepsins failed
to protect cancer cells against kahalalide’s F cytotoxicity. Janmaat et al.271 identified ErbB3, a
downstream molecule of the PI3K-Akt pathway, as an important determinant of the cytotoxic
activity of kahalalide F in vitro. Appert-Collin et al.272 have recently reviewed the roles of ErbB
receptors in cancer cell migration and invasion, while Mayer and Arteaga273 comprehensively
reviewed the PI3K-Akt pathway as a target for cancer treatment.
Pardo et al.274 reported that kahalalide F was found to be COMPARE-negative when it
was tested in the NCI 60 cell line panel. Kahalalide’s F GI50 values in the NCI 60 cell line panel
ranged between 0.2 and 10 μM, with hormone-independent prostate cancer cells being most
sensitive to this compound.274 Ling et al.275 report that kahalalide F was then shown to have a
strong correlation between cytotoxicity and high c-erbB2 mRNA expression levels.275
Sua´rez et al.269 reported that normal cells are 5–40 times less sensitive to kahalalide F
than cancer cells. in vivo, kahalalide F demonstrated activity against human prostate hormone-
independent xenograft models274,276,277 and in the hollow fiber assay.263
Kahalalide F underwent several clinical trials in oncology and entered Phase II but without
much success.278 For example, Martı´n-Algarra et al.279 evaluated the antitumor response of
Medicinal Research Reviews DOI 10.1002/med
732  CIAVATTA ET AL.
kahalalide F in advanced malignant melanoma patients in a Phase II study; however, while
kahalalide F was well tolerated by the patients, this trial was closed after the first stage because
of the lack of an objective response. Iso-kahalalide F, a regioisomer of kahalalide F, also
entered Phase II clinical trials for liver cancer, melanoma, and NSCLC patients, but failed to
be effective as well.280
Elisidepsin (PM02734, Irvalec R©; 15b; Fig. 6) is a synthetic marine-derived cyclic peptide
of the kahalalide F family that also entered clinical development.281–283 Its GI50 values ranged
between 0.4 and9μMinapanel of 23 cancer cell lines frombreast, colon, head andneck, lung,
ovary, pancreas, prostate, and melanoma origins.281 Herrero et al.284 showed that elisidepsin
induces necrosis-like cell death in yeast Saccharomyces cerevisiae used as a model system. They
also demonstrated that the cell membrane and, in particular, cell membrane components like
2-hydroxy fatty acid-containing ceramides, are important for elisidepsin’s activity. Elisidepsin-
induced necrosis-like cell death was also experimentally shown by Va´radi et al.285 and also
recently by Molina-Guijarro et al.,286 who demonstrated that elisidepsin interacts directly with
glycosylceramides in the plasmamembrane of cancer cells.Kiraly et al.287 observed that hypoxia
reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of
lipid rafts. In addition, Teixido et al.288 reported that acquired resistance to elisidepsin in cancer
cells is associated with a switch to the epithelial-mesenchymal transition (EMT) state, which
may be seen as a hallmark of cancer progression to the invasive and metastatic disease.289
This compound displayed in vivo anticancer activity against human melanoma, liver, pancreas,
breast, and prostate cancer xenografts.290
Clinical trialswith elisidepsinhave so far produceddisappointing results. For example,while
elisidepsin presented an acceptable safety profile, it was not recommended for further evaluation
in advanced or metastatic gastroesophageal cancer due to the absence of activity.291 Similar
conclusions were reached byGoldwasser et al.282 for other types of malignancy. Other members
of the kahalalide family that display cytotoxic activity against cancer cells are described in the
comprehensive review by Gao and Hamann.263
D. Potentially Promising Anticancer Agents Derived from Mollusks
Compounds here considered do not include proteins and other substances with molecular
weight higher than 2000 amu. Although we made a significant effort to find mollusk-derived
compounds showing in vitro growth inhibitory activity against cancer cell lines at a concen-
tration of < 10 μM, we are cognizant that some substances could have escaped our attention.
Compounds under review are listed alphabetically in Table II along with their possible origin
if described in the literature. The information on classification, distribution, and alimentary
habits of themollusks under review is summarized in Table I, while Figure 1 shows photographs
of selected species. All the NCI data that we report below (if available) were obtained on the
public NCI website at https://dtp.cancer.gov/databases_tools/data_search.htm.
1. Terpenes and Steroids
Unusual acetates of halogenated monoterpenes have been characterized from a Spanish pop-
ulation of Aplysia punctata (Fig. 1B; Table I). Among them, compounds 16–18 (Fig. 7; Table
II under halogenated monoterpenes) displayed GI50 values ranging between 4 and 10 μM in
four cancer cell lines.292 Another linear halogenated monoterpene (19; Fig. 7; Table II) was
isolated from two specimens of Aplysia dactylomela (Fig. 1A; Table I) collected from different
sites along the Spanish coast.293 This compound displayed growth inhibitory effects against
HM02 (gastric carcinoma), HEP-G2 (liver carcinoma), and MCF-7 (breast carcinoma) cancer
cells with the GI50 values of 3 μM.293
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Figure 7. Chemical structures of acetates of halogenated monoterpenes (compounds 16-19), caulerpenyne
(20), (-)-aplysin (21), aplysistatin (22), elatol (23), obtusol (24a), isoobtusol (24b), 1-formamido-10(1→2)-
abeopupukeanane (25a), and 2-formamidopupukeanane (25b).
Caulerpenyne (20; Fig. 7; Table II) is a sesquiterpene possessing a 1,4 diacetoxy-butadiene
moiety found in algae of genus Caulerpa and in several sacoglossan mollusks (including Elysia
subornata; Fig. 1E; Table I) that feed on these organisms.294,295 The average GI50 for cauler-
penyne is 10 μM in various cancer cell lines assayed in academic laboratories.296–298 The
GI50 value reported by the NCI for caulerpenyne in the 60 cell line panel is 40 μM and a
COMPARE analysis with a cut-off correlation at p = 0.7 is negative in the standard agent
dataset. No selectivity was noted with respect to a given histological type of cancer cell lines in
this panel. In the same manner, caulerpenyne does not display bioselectivity between normal
(hamster fibroblasts, human keratinocytes, and melanocytes) and cancer cells.298,299 Barbier
et al.298 reported that this compound induces aggregation of tubulin, which may be responsible
for the inhibition of tubulin polymerization and bundling of residual microtubules. Bourdron
et al.300 then showed that it does not bind to colchicine, taxol, and vinca-alkaloid binding
domains. Caulerpenyne blocks the stimulation of mitogen-activated protein kinase (MAPK),
which participates in the control of cell functions such as proliferation, differentiation, and
death.298,301
One of the first halogenated metabolites isolated from a marine source was (-)-aplysin
(21; Fig. 7; Table II), which was found in the anaspidean mollusk Aplysia kurodai (Table I).302
Although this algal dietary sesquiterpene was originally described as an antifeedant, later it was
reported to induce growth inhibitory effects in various cancer cell lines withGI50 values ranging
between 4 and 8 μM.303 The mean GI50 value reported by the NCI in the 60 cell line panel was
30 μM and a COMPARE analysis with a cut-off correlation at p = 0.7 was negative in the
standard agent dataset. No selectivity was shown with respect to a given histological type of
cancer cell lines in theNCI panel. Aplysin did not display in vivo anticancer activity in themouse
P388 leukemia model used by the NCI. However, it displayed marginal effects in the human
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A549 NSCLC xenograft with 18% of tumor growth reduction as compared to the control.79
Liu et al.79 showed that aplysin acts as a sensitizer for tumor necrosis factor related apoptosis
inducing ligand (TRAIL) induced apoptosis in cancer cells and that these effects occurred via
the P38 MAPK/survivin pathway. It sensitized TRAIL-induced in vivo anticancer activity in
the humanA549NSCLC xenograft model.79 As reported by Liu et al.,79 TRAIL has served as a
biological agent for cancer treatment for decades. Yet, clinical trials have not shown significant
survival benefit in cancer patients. Great hopes are thus placed on innovative compounds that
would be able to significantly sensitize apoptosis-resistant cancer cells to TRAIL. Aplysin also
sensitizes the cytotoxic effects of the alkylating drug temozolomide against human glioma cells
by increasing miR-181 expression, which acts as a glioma tumor suppressor.304 In addition,
aplysin (21) induces cell cycle arrest and apoptosis in glioma cells through the inhibition of the
PI3K/Akt signaling, which plays important roles in glioma cell survival.304 Glioblastoma, the
most malignant form of glioma, displays dismal prognoses because of major mechanisms of
resistance to pro-apoptotic stimuli.68
A 2-propanol extract of the sea hare Aplysia angasi (also named A. dactylomela; Fig.
1A; Table I) displayed growth inhibitory activity against murine lymphocytic leukemia P338
cells.305 The active compound, aplysistatin (22; Fig. 7; Table II), was obtained by bio-guided
fractionation, and identified as a brominated tricyclic 6-7-5-fused sesquiterpene, in which the
seven-membered ring contains a bridging oxygen atom and the five-membered ring is a lactone.
Aplysistatin displayed the GI50 value of 8 μM against human KB cancer (an oral cancer
cell line but cross-contaminated by HeLa cervix carcinoma cells115) and mouse P388 leukemia
cells.305
Several halogenated chamigrene sesquiterpenes were isolated from A. dactylomela
(Fig. 1A; Table I) collected off Canary Islands.293Among these metabolites of dietary algal
origin are elatol (23; Fig. 7; Table II) and obtusol (24a; Fig. 7; Table II). Elatol was first iso-
lated from Laurencia elata.306 Lang et al.307 report that several species of Laurencia (red algae)
produce elatol as a major secondary metabolite, especially Laurencia microcladia from which
elatol was obtained with a yield of ca. 10% (w/w) from the ethanolic extract of the algae.
Isoobtusol (24b; Fig. 7; Table II) was isolated for the first time from Laurencia obtusa.308 Elatol
displays GI50 values ranging between 1 and 10 μM against about ten cancer cell lines that were
assayed by various academic laboratories.293,309,310 While normal Vero (African green monkey
kidney) cells displayed weaker sensitivity to elatol-induced growth inhibitory effects (GI50 = 25
μM),309 normal L929 murine fibroblasts displayed sensitivity similar to cancer cells (GI50 = 1
μM).310 Elatol cannot therefore be considered as a bioselective compound. It is a cytotoxic and
proapoptotic compound in murine B16F10 melanoma cells through a decrease in Bcl-x and
an increase in Bak, caspase-9, and p53 expression.310 B16F10 melanoma cells are known to be
very sensitive to proapoptotic stimuli.119,311 It is therefore not surprising that elatol decreased
in vivo the growth of B16F10 melanoma growing subcutaneously (s.c.) in syngeneic mice.310
It would interesting to know how efficient elatol is against B16F10 melanoma cells that are
intravenously transplanted in syngeneic mice and lead to aggressive lung pseudometastases.311
Indeed, the murine B16F10 melanoma model is not at all representative of the great major-
ity of human melanomas associated with dismal prognoses that display marked resistance
to proapoptotic stimuli.67 Obtusol and isoobtusol display weaker in vitro growth inhibitory
activity than elatol.293,307,309
Two sesquiterpenes named 1-formamido-10(1→2)-abeopupukeanane (25a; Fig. 7; Table
II under pupukeanane derivatives) and 2-formamidopupukeanane (25b; Fig. 7; Table II) were
recently isolated and chemically characterized from the nudibranch Phyllidia coelestis (Fig.
1L; Table I).312 As emphasized by Jaisamut and colleagues,312 tubercle nudibranchs of the
genus Phyllidia graze on sponges and can sequester specific sponge metabolites. For example,
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Figure 8. Chemical structures of reticulidins A (26a) and B (26b), oculiferane (27), epi-obtusane (28), parguerol
(29a), parguerol-16-acetate (29b), isoparguerol (29c), isoparguerol-16-acetate (29d), deoxyparguerol (29e), and
dorisenone A (30a), B (30b), C (30c), and D (30d).
P. varicosa secretes in its mucus 9-isocyanopupukeanane that is lethal to crustaceans and arises
from its sponge prey Ciocalypta sp. (ex. Hymeniacidon sp.). Both compounds 25a and 25b
display in vitro growth inhibitory activity in the range between0.1 and7μM in four distinct
human cancer cell lines.312 Also, both of them display some levels of bioselectivity. Specifically,
they inhibited by 65 and 25%, respectively, the growth of human gingival fibroblasts when
assayed at 5 μM.312
Reticulidin A (26a; Fig. 8; Table II) and B (26b; Fig. 8; Table II) are two carbonimidic
chlorinated sesquiterpenes that have been isolated from the Okinawan nudibranch Reticulidia
fungia (Table I).313 The in vitroGI50 values displayed by compounds 26a and 26b were 1 μM
inKB cells, and2 and0.3 μM inmouse L1210 leukemia cells, respectively.313 As mentioned
above, tubercle nudibranchs of the genusPhyllidia feed on their sponge prey from theCiocalypta
genus,312 and thus, the possibility remains that the nudibranch R. fungia also feeds on sponges,
which could belong to Pseudoaxinyssa pitys, Stylotella aurantium, and Axinyssa sp. genera.313
Two novel halogenated sesquiterpenes were isolated from the digestive glands of the Egyp-
tian sea hare Aplysia oculifera (Table I).314 These two compounds, oculiferane (27; Fig. 8; Table
II) and epi-obtusane (28; Fig. 8; Table II), displayed GI50 values ranging between 2 and 8
μM in a minipanel of five human cancer cell lines including the PC-3 prostate, A549 NSCLC,
MCF-7 breast, HepG2 liver, and HCT116 colon cancer models.314
Parguerol (29a; Fig. 8; Table II), parguerol-16-acetate (29b; Fig. 8; Table II), isoparguerol
(29c; Fig. 8; Table II), isoparguerol-16-acetate (29d; Fig. 8; Table II), and deoxyparguerol (29e;
Fig. 8; Table II) are tricyclic monobromoditerpenes isolated from A. dactylomela (Fig. 1A;
Table I).315 The algal origin of these metabolites could be strongly suggested as they were
isolated from the digestive gland of this anaspidean mollusk.315 Indeed, these metabolites were
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Figure 9. Chemical structures of the other spongian diterpenoids include 7α-hydroxyspongian-16-one
(31a), 15α,16α-diacetoxy-11,12β-epoxyspongian (31b), 7α-acetoxydendrillol-3 (31c), 7α-acetoxy-17β-hydroxy-
15,17-oxidospongian-16-one (31d), 11β-hydroxyspongi-12-en-16-one (31e), spongian-16-one (31f), 7α-
acetoxyspongian-16-one (31g), and palmadorins (A: 32a; B: 32b; D: 32c; M: 32d; N: 32e; O: 32f).
identified by Awad316 in the red alga Jania rubens (L.) Lamx. collected from the Red Sea
coast at Hurghada (Egypt) and it is known that some Aplysia species can feed on sponges.315
It is interesting to note that the complex chemical mixtures obtained from A. dactylomela
collected from la Parguera (Puerto Rico) versus the ones from Bimini (Bahamas) do not have
any common components.315 The five compounds displayed in vitro growth inhibitory activity
in low micromolar ranges but they were tested on one cancer cell line only, the murine P388
leukemia,315 which is highly sensitive to proapoptotic stimuli.317 Awad316 confirmed the data
obtained by Schmitz et al.,315 but once more on highly apoptosis-sensitive cancer cells, Ehrlich
ascite carcinoma. Both Schmitz et al.315 and Awad316 showed that isoparguerol derivatives
displayed slightly higher in vitro growth inhibition of cancer cells than those of parguerol.
A series of dorisenones (30a-30d; Fig. 8; Table II) and related spongian diterpenoids (31a-
31g; Fig. 9; Table II) were isolated from the Japanese nudibranch Chromodoris obsoleta (also
named Goniobranchus obsoletus; Table I).318 Compounds 30a-30d and 31a-31g displayed GI50
values ranging between submicromolar and low micromolar in mouse L1210 leukemia and
human KB cells.318 Compounds 31d and 31g were assayed in vivo in the P388 leukemia model
but displayed no activity.318
A chemical study of theWesternAntarctic Peninsula nudibranchAustrodoris kerguelenensis
(also named Doris kerguelenensis; Table I) led to the characterization of a series of about 20
clerodane, labdane, and halimane diterpene glyceride esters, named palmadorins (palmadorin
A to palmadorin Q).319,320 Palmadorin A (32a), B (32b), D (32c), M (32d), N (32e), and O (32f)
(Fig. 9; Table II) inhibit human erythroleukemia (HEL) cell proliferation with low micromolar
GI50 values, while palmadorin M was shown to inhibit JAK2, STAT5, and Erk1/2 activation
in HEL cells, and cause apoptosis at 5 μM. These HEL cells represent the AML-M6 model of
acute erythroleukemia, a rare (3% of cases) form of acute myeloid leukemia (AML), in which
erythroblastic precursors cause the myeloproliferation.320
Medicinal Research Reviews DOI 10.1002/med
MARINE MOLLUSK-DERIVED AGENTS WITH ANTIPROLIFERATIVE ACTIVITY  737
Figure 10. Chemical structures of dichlorolissoclimide (33a), chlorolissoclimide (33b), haterumaimides (A: 33c;
B: 33d; C: 33e; D: 33f; E: 33g; F: 33h; G: 33i; H: 33j; I: 33k; J: 33l; K: 33m; N: 33n; O: 33o; P: 33p; Q: 33q; L:
34a; M: 34b), 3β-hydroxychlorolissoclimide (34c), a lissoclimide-type alkaloid (34d), and inorolides A (35a), B
(35b), and C (35c).
A series of interesting bioactive succinimide-containing labdane terpenoids have been iso-
lated from ascidians of the genus Lissoclinum since 1991. Dichlorolissoclimide321,322 (33a;
Fig. 10; Table II) and chlorolissoclimide323 (33b; Fig. 10; Table II) were reported from an ascid-
ian collected in New Caledonia, whereas haterumaimides A-E324 (33c-33g; Fig. 10; Table II),
F-I325 (33h-33k; Fig. 10; Table II), J-K326 (33l-33m; Fig. 10; Table II), and N-Q327 (33n-33q;
Fig. 10; Table II) were all isolated from Lissoclinum ascidians collected off Hateruma Islands.
In 2004, new haterumamide-type diterpenes, haterumamides L (34a; Fig. 10; Table II), M (34b;
Fig. 10; Table II), and 3β-hydroxylissoclimide (34c; Fig. 10; Table II) have been found in two
Notaspidean mollusks, Pleurobranchus albiguttatus and P. forskalii, along with chlorolisso-
climide, dichlorolissoclimide, haterumamides B, D, and H by Fu et al.328 As suggested by the
authors,328 these labdanes are presumably metabolites of a Lissoclinum species of the ascidian
on which the mollusks feed.
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Chlorolissoclimide (33b), dichlorolissoclimide (33a), and haterumaimide D (33f) displayed
GI50 values of0.08,0.08, and1μM in theNCI 60 cell line panel, respectively, and 33a and
33b (but not 33f) showed selectivity toward melanoma cell lines.328,329 Chlorolissoclimide (33b)
and dichlorolissoclimide (33a) also displayed marked growth inhibitory effects in the Corbett–
Valeriote soft agar disk diffusion assay, while they showed no solid tumor selectivity.328 In
contrast, while less active than 33b and 33a, 3β-hydroxychlorolissoclimide (33c) displayed solid
tumor selectivity (thus potential bioselectivity) in this soft agar assay.328 The Corbett-Valeriote
soft agar disk diffusion assay detects differences in zones of inhibition between a solid tumor
cell line (Colon38, ColonH116, LangH125) and either leukemia (L1210 or CEM) or normal
(CFU-GM) cells.330
On the other hand, GI50 values for haterumaimides J (33l) and K (33m), haterumaimides
C (33e), G (33i), and I (33k) range between 0.5-1 nM (33l and 33m) and >20 μM (33e, 33i
and 33k).327 Uddin et al.327 report that based on an SAR analysis, it appears that the presence
of hydroxyl groups at C-6, C-7, C-12, and C-18; the chlorine atom at C-2; and the imido NH
in ring C are very important for haterumaimide-induced in vitro growth inhibitory effects in
P388 leukemia cells. A recent synthesis of lissoclimide-type compounds has been published
by Gonzalez et al.331 One of these synthesized compounds, specifically 34d, displayed GI50
values of 12 μM in human HeLa cervix epithelia carcinoma and Junket acute lymphoblastic
leukemia cells, while the GI50 value of compound 34d was 80 μM in normal Vero (African
green monkey [Cercopithecus aethiops] kidney) cells, suggesting bioselectivity properties for
compound 34d. The synthesis of chlorolissoclimide (33b) was published by Quinn et al in
2016.332 Chlorolissoclimide (33b) and dichlorolissoclimide (33a) are active against murine P388
leukemia cells resistant to adriamycin.328,333 Robert et al.334 demonstrated that chlorolisso-
climide (33b) and dichlorolissoclimide (33a) exert their growth inhibitory effects through the
blockade of translation elongation by inhibiting translocation, leading to the accumulation of
ribosomes on mRNA. At concentrations relevant to the marked protein synthesis inhibition,
DNA synthesis and RNA transcription are slightly or not affected.334 Robert et al.334 also
reported that chlorolissoclimide (33b) does not induce a loss of polysomes in contrast to other
inhibitors of elongation, such as phyllanthoside and nagilactone C. These authors emphasize
that (i) the ribosome recruitment phase of translation initiation is usurped in many human
cancers, (ii) several inhibitors of elongation have been previously tested as anticancer agents in
preclinical animal models and clinical trials, and (iii) the selectivity of these general inhibitors
for cancer cells may stem from the fact that cancer cells have higher translation rates than do
normal cells.334 One protein synthesis inhibitor, the Cephalotaxus alkaloid homoharringtonine
(an inhibitor of translation elongation), has been approved by the FDA for the treatment of
adult patients with chronic myeloid leukemia displaying resistance and/or intolerance to two
or more tyrosine kinase inhibitors.335 The clinical data obtained with this compound have been
recently reviewed by Heiblig et al.336 and Kantarjian et al.337
Several sesterterpenoids were isolated from Japanese specimens of the nudibranch Chro-
modoris inornata (also named C. aspersa; Table I).338 These compounds were assayed in vitro
for growth inhibition against the humanKB and the murine L1210 leukemia cell lines.338 These
compounds and their GI50 values are inorolide A (35a; Fig. 10; Table II; GI50 = 7 μM),
inorolide B (35b; Fig. 10; Table II; GI50 = 5 μM), inorolide C (35c; Fig. 10; Table II; GI50 =
4 μM), deoxoscalarin (36a; Fig. 11; Table II; GI50 = 3 μM), and several of its analogues,
namely deoxoscalarin-3-one (36b; Fig. 11; Table II under sesterterpenoids; GI50 =2μM), 21-
hydroxydeoxoscalarin (36c; Fig. 11; Table II; GI50 = 9 μM), 21-acetoxydeoxoscalarin (36d;
Fig. 11; Table II; GI50 = 1 μM), and 12-O-acetyl-16-O-deacetyl-12,16-episcalarolbutenolide
(37; Fig. 11; Table II under sesterterpenoids; GI50 = 5 μM).338 Some of these compounds
have also been isolated from marine sponges from the Hyrtios genus.338 We recently reviewed
the anticancer activity associated with sesterterpenoids from different origins.339
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Figure 11. Chemical structures of deoxoscalarin (36a) and several of its analogues, that is, deoxoscalarin-3-one
(36b), 21-hydroxydeoxoscalarin (36c), and 21-acetoxydeoxoscalarin (36d), 12-O-acetyl-16-O-deacetyl-12,16-
episcalarolbutenolide (37), aurilol (38a), and enshuol (38b).
The bromotriterpene aurilol (38a; Fig. 11; Table II ) was isolated from the digestive gland
of the sea hare D. auricularia (Fig. 1D; Table I), with a GI50 value of 7 μM against hu-
man HeLa S3 cancer cells.340 Aurilol is related to enshuol (38b; Fig. 11; Table II ), a bromo
triterpenic polyether with a dioxabicyclo(5.4.0) undecane ring system, isolated from the algae
Laurencia, suggesting that 38a is most likely dietary.340 The complete synthesis of aurilol (38a)
was accomplished in 2005 by Morimoto et al.341
The bromotriterpene polyether aplysqualenol A (39, Fig. 12; Table II ) has been isolated
from the Caribbean sea hare A. dactylomela (Fig. 1A; Table I).342 It was submitted to the NCI
one-dose primary assay in the cancer 60 cell line panel and found to display GI50 values of
0.4 μM in the human SNB-19 central nervous system cancer and the T-47D breast cancer
cell lines.342 The GI50 values were >10 μM in the remaining cancer cell lines.342 Vera et al.343
discovered that aplysqualenol is a ligand for the light chain of dynein type 1 (DYNLL1), which
is suggestive of potential development of small-molecule regulators of the dynein complex344
with applications in cancer treatment.345,346
Thyrsiferol (40; Fig. 12; Table II ) is a brominated triterpene polyether first isolated from
the tropical marine red algae Laurencia thyrsifera J. Agardh (Rhodomelaceae),347 and more
recently also found in the sea hare A. dactylomela (Fig. 1A; Table I) from the South China
Sea.348 Mahdi et al.349 stated that thyrsiferol displays potent in vitro growth inhibitory activity
in the mouse P388 leukemia cell line, while Ferna´ndez et al.350 found that this compound
displayed moderate growth inhibitory activity in cell lines originating from solid tumors with
GI50 values of 0.02 and 17 μM in P388 and A549 NSCLC cancer cells, respectively.350
It must be emphasized that P388 leukemia cells display dramatic sensitivity to proapoptotic
stimuli,317 while A549 NSCLC cells are moderately resistant.351 These data thus point to the
fact that thyrsiferol is indeed more active in vitro against apoptosis-sensitive cancer cells than
their resistant counterparts. Mahdi et al.349 showed that thyrsiferol inhibits hypoxia-induced
HIF-1 activation in T47D human breast tumor cells and suppressed hypoxic induction of HIF-
1 target genes (VEGF and GLUT-1) at the mRNA level.349 They also reported that thyrsiferol
suppressed mitochondrial respiration at complex I.
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Figure 12. Chemical structures of aplysqualenol A (39), thyrsiferol (40), 3-epi-aplykurodinone B (41), an en-
doperoxide sterol (42), a C-21 hydroxylated sterol (43), a secosterol (44), and a prenylated hydroquinone (45).
The degraded sterol 3-epi-aplykurodinone B (41; Fig. 12; Table II ) was isolated from a
Spanish collection of Aplysia fasciata (Table I) and it displayed GI50 values of 8 μM in four
cancer cell lines including mouse P388 leukemia, and human A549 NSCLC, HT-29 colon
cancer, and SKMEl-28 melanoma.352
An endoperoxide sterol (42; Fig. 12; Table II ) was isolated from the digestive gland of
Aplysia depilans (Table I) and its structure confirmed later by synthesis.353 This compound
displays a GI50 value of 3 μM in human HCT-116 colorectal cancer cells.354
Trimusculus is a shelled pulmonate mollusk (Table I) living in the intertidal zone of rocky
shores.355 An unusual C-21 hydroxylated sterol (43; Fig. 12; Table II ) was isolated from T.
peruvianus (living on Chilean coasts, Table I), and displayed GI50 values of 6 μM against
human HCT-116 and HT29 colon cancer cell lines.356 More recently, a novel secosterol (44;
Fig. 12; Table II ) was isolated and characterized from a population of T. costatus (Table I)
collected in South Africa.357 Compound 44 displays the GI50 value of 3 μM in the WHCO1
esophageal cancer cell line.357
Among numerous metabolites isolated from the arminacean nudibranch Leminda millecra
(Table I), including among others six sesquiterpenes and eight prenylquinones,358 only one
compound, prenylated hydroquinone 45 (Fig. 12; Table II ), displayed moderate in vitro growth
inhibitory activity with GI50 values of 6 and 9 μM in the human WHCO1 and WHCO6
esophageal cancer cell lines, respectively.359 The compounds described above could be from soft
coral (Alcyonium fauri, e.g.) or gorgonian (Leptogorgia palma, e.g.) origin because these are the
preys of L. millecra.358
2. Peptides and Depsipeptides
Metabolites of this class have been isolated from a wide range of mollusks belonging to dif-
ferent subclasses of gastropods and diverse orders of opisthobranchs as well as other benthic
invertebrates.360,361 These compounds are most likely produced by symbiotic cyanobacteria,
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Figure 13. Chemical structures of doliculide (46), jasplakinolide (47), phalloidin (48), chondroamide C (49), and
kulolide 1 (50).
as they share very similar structures.362,363 However, we will describe here all the substances
reported from mollusks even if they have been later found to be of cyanobacterial origin, while
clearly indicating the origin of each compound in Tables I and II.
Doliculide (46; Fig. 13; Table II ), which has been isolated from Japanese specimens of the
anaspidean D. auricularia (Fig. 1D; Table I),364 is a compound of mixed peptide–polyketide
biogenesis characterized by the presence of an iodo-N-Me-tyrosine and one unit of glycine. This
compound exhibits marked growth inhibitory effects (GI50 = 2 nM) against human HeLaS3
cervix carcinoma cells.364 Total enantioselective syntheses of doliculide were reported first by
Ishiwata and colleagues,365 and then byGhosh and Liu366 andMatcha et al.367 Doliculide binds
to actin and consequently arrests cancer cells at the G2/M phase of the cell cycle by interfering
with normal actin assembly.368 Like jasplakinolide (47; Fig. 13), a cyclodepsipeptide isolated
from marine sponges of Jaspis species,366 doliculide causes the hyperassembly of purified actin
into F-actin.368 Doliculide, like jasplakinolide, displaces phalloidin (48; Fig. 13), a cyclic pep-
tide isolated from the mushroom A. phalloides,245 from actin polymer.368 Similar effects were
also observed with other depsipeptides known as chondramides.368 Chondramides, such as
chondroamide C (49; Fig. 13), are isolated from myxobacteria of the genus Chondromyces.369
Bai et al.368 used a computer-driven shape descriptor analysis370 to gain insight into a possi-
ble pharmacophore shared by doliculide, jasplakinolide, phalloidin, and chondramide C that
would explain the apparent binding of this diverse group of substances at the same site on
F-actin. They found that the segment of doliculide that best overlapped with the three other
compounds encompassed its phenyl and isopropyl side chains and the portion of the macro-
cycle between these substituents (Fig. 13). Matcha et al.367 validated these findings by using
unbiased computational docking.
Treatment of humanMCF-7 andMDA-MB-231 breast cancer cells with doliculide leads to
inhibition of proliferation and impairs the migratory potential of these cancer cells.371 Foerster
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et al.372 quite recently showed that doliculide treatment of p53 wild-type cancer cells alters
up to 13% of senescence-related genes at nontoxic concentrations. Like tubulin, actin is also
implicated in the metastatic process.373–375
Cyclodepsipeptide kulolide 1 (50; Fig. 13; Table II ) was isolated from the cephalaspidean
mollusk Philinopsis speciosa (Table I) collected off Hawaii.376 Kulolide 1 displays growth in-
hibitory activity inmicromolar range against murine L-1210 (GI50 =1μM) and P388 (GI50 =
3 μM) leukemia cells.376 It must be emphasized once more that L1210 and P388 leukemia
cells are highly sensitive to proapoptotic stimuli.317
Kulokekahilide-1405 (51a; Fig. 14; Table II ) and kulokekahilide-2378 (51b; Fig. 14;
Table II ) are cyclic bidepsipeptides isolated from P. speciosa (Table I), which is a carnivorous
mollusk.378 One of the preys of P. speciosa is the sea hare Stylocheilus longicaudus, which feeds
on cyanobacteria.379 The possibility thus remains that compounds isolated from P. speciosa
could have a cyanobacterial origin.
Kulokekahilide-1 displays growth inhibitory effects with the GI50 of 2 μM in murine
P388 leukemia cells,377 while kulokekahilide-2 displays higher potency in this cell line with a
GI50 value of4 nM.378 In addition, kulokekahilide-2 displayedGI50 values of8 and15 nM
in the human SK-OV-3 ovarian and the MDA-MB-435 breast cancer cell lines, respectively.378
The mean GI50 value calculated for the three P388, SK-OV-3, and MDA-MB-435 cancer cell
lines is thus 9 nM. Because the GI50 value of kulokekahilide-2 in A-10 (nontransformed rat
[Rattus norvegicus] aortic cells) cell line is 60 nM,378 it behaves as a bioselective compound,
at least within the few cell lines in which it has been assayed. In the study reported by Umehara
et al.,380 the mean GI50 value of kulokekahilide-2 was 0.2 nM in three other cancer cell lines,
namely humanA549NSCLC, K562 chronic myelogenous leukemia, andMCF-7 breast cancer.
In the study reported by Takada et al.,381 the GI50 values for kulokekahilide-2 (51b) were 19
and 4 nM in murine P388 leukemia and human HeLa cervix carcinoma cells, respectively.
Umehara et al.380 used the CellTitler-Blue Cell Viability Assay with a 72-hr period of cell-drug
incubation, while Takada et al.381 used the MTT colorimetric assay incubating cells with the
compound for 96 hr. The different methods to evaluate the growth inhibition could explain, at
least partly, why kulokekahilide-2 appeared to be at least tenfold more potent in the study of
Umehara et al.380
Among the series of kulokekahilide-2 analogues synthesized by Umehara et al.,380 com-
pounds 51c (Fig. 14) and 51d (Fig. 14) were about 100-fold more potent than kulokekahilide-2
with GI50 values of0.001 and0.008 nM, respectively. In contrast, compounds 51e (Fig. 14)
and 51f (Fig. 14) were completely devoid of in vitro growth inhibitory activity in A549, K562,
and MCF-7 cancer cell lines with GI50 values >10 μM.380 These authors thus conclude that
the addition of halogen at the para position of the phenyl group in the 24-D-MePhe residue in
kulokekahilide-2 remarkably increased in vitro growth inhibitory activity. The kulokekahilide-2
derivatives generated by Takada et al.381 did not display higher in vitro growth inhibitory effects.
Suenaga et al.382 reported the isolation of the cyclic depsipeptide aurilide (52a; Fig. 14;
Table II ) from Japanese specimens of D. auricularia (Fig. 1D; Table I). It must be noted that
aurilides B (52b; Fig. 14) and C (52c; Fig. 14), which are closely related to aurilide, were isolated
from a Papua New Guinea collection of the marine cyanobacterium L. majuscula.383
Aurilide was assayed in the NCI 60 cell line panel and this analysis revealed the mean GI50
value of 0.01 μM, with selectivity toward ovarian, renal, and prostate cancer cell lines.384
It also displayed marked in vivo anticancer activity in the NCI hollow fiber assay (detailed
by Hollingshead et al.385), while it was inactive in a xenograft model (that was unfortunately
not described in detail by Suenaga et al.384) because of high toxicity. Aurilide shows marked
microtubule stabilization properties, while it does not seem to interact directly with tubulin;
its mechanism of action thus appears to be distinct from that displayed by taxol.384 Aurilide
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Figure 14. Chemical structures of kulokekahilides 1 (51a) and 2 (51b), kulokekahilide-2 derivatives (51c-51f),
aurilide (52a), and aurilides B (52b) and C (52c).
selectively binds to prohibitin 1 (PHB1) in the mitochondria and activates the proteolytic
processingof optic atrophy1 (OPA1) that results inmitochondria-induced apoptosis.386 Because
in the NCI testing aurilide showed no differences in its growth inhibitory effects in apoptosis-
sensitive versus apoptosis-resistant cancer cell lines,384 it thus appears that this compound can
overcome various types of cancer cell resistance to proapoptotic stimuli. Semenzato et al.387
emphasize that proapoptotic drugs targeting themitochondrial Bcl-2 rheostat of apoptosis have
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Figure 15. Chemical structures of keenamide A (53), cycloforskamide (54), onchidin (55a), and onchidin B
(55b).
potential to selectively kill cancer cells. Semenzato et al.387 thus argue that the study by Sato
et al.386 adds to the available anticancer strategies by identifying the target of aurilide in the
PHB1/OPA1-dependent apoptotic cristae remodeling. The reader interested in the overview
of the various types of resistance patterns to cytotoxic insults displayed by the 60 cancer cell
lines used by the NCI is referred to the studies by Shoemaker115 for an overall overview,
Ikediobi et al.126 for mutation analysis of 24 known cancer genes, Shankavaram et al.127 for
transcript and protein expression profiles, Blower et al.128 for microRNA expression profiles,
and Gholami et al.129 for a global proteome analysis. Shankavaram et al.388 also present the
CellMiner tool, which is a relational database and query tool for the NCI 60 cancer cell line
panel.
Keenamide A (53; Fig. 15; Table II ) is a cyclic peptide isolated from the gastropod
notaspidean P. forskalii (Table I) off Manado in Indonesia.389,390 Its GI50 values range between
4 and 8 μM in four cancer cell lines.389
Another macrocyclic peptide, cycloforskamide (54; Fig. 15; Table II ), was recently iso-
lated from P. forskalii (Table I), but off Ishigaki Island (Japan).390 Cycloforskamide could
be a symbiont-derived peptide conferring beneficial effects to the host organism because P.
forskalii belongs to the family of opportunistic carnivorous mollusks.390 Its GI50 value is 6
μM in murine P388 leukemia cells.390 Once more, let us emphasize the high chemosensi-
tivity level of P388 leukemia cells, making therefore this model poorly representative of the
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clinical cancer,317 which is the reason for why the NCI abandoned this model several decades
ago.115
The methanolic extract of the pulmonate mollusk Onchidium sp.1 (Table I) subjected to
activity-guided fractionation using murine P388 leukemia and human KB oral cancer cells
afforded cytotoxic onchidin (55a; Fig. 15; Table II ).391 Later, a newmetabolite named onchidin
B (55b; Fig. 15; Table II ) was isolated from the same animal.392 These two cyclic depsipeptides
display GI50 values of 7 μM in P388 and KB cancer cells.392
3. Polyketides
Polyketides comprise a wide array of compounds, most commonly sharing a common feature,
such as a macrolide ring. As for cyclic depsipeptides, the true origin of macrolidic compounds
has been postulated to be microorganisms. For instance bryostatins are complex macrocyclic
lactones isolated from bryozoans, whose real origin has been attributed to bacteria after the
identification of putative biosynthetic genes in the uncultured symbiotic bacterium “Candidatus
Endobugula sertula.”393,394 As for peptides, we will discuss all polyketide compounds isolated
from mollusks (Tables I and II).
A bioguided fractionation of a Japanese collection of the sea hare D. auricularia (Fig.
1D, Table I) led to the isolation of two macrolide glycosides, auriside A (56a; Fig. 16; Table
II ) and auriside B (56b; Fig. 16; Table II ).395 From the chemical point of view aurisides
have unique structures. Indeed, the aglycon possesses a new type of carbon backbone, 5,7,13-
trihydroxy-3,9-dioxoheptadecanoic acid, and contains a bromine-substituted conjugated diene
moiety, a 14-membered lactone, and a cyclic hemiacetal part.395 Auriside A with the GI50 of
0.2 μM displays more potent growth inhibitory effects than auriside B (GI50 = 2 μM)
in human HeLaS3 cervix cancer cells.395 Various chemical syntheses of aurisides have been
reported.396,397 As mentioned earlier, dolastatin 19 (57) shares significant structural similarities
with aurisides A (56a) and B (56b).
Suenaga et al.398 isolated auripyronesA (58a; Fig. 16; Table II) andB (58b; Fig. 16; Table II)
from the digestive gland of Japanese specimens of D. auricularia (Fig. 1D; Table I). These two
compounds display theGI50 of0.5μMin humanHeLaS3 cells.398 Various chemical syntheses
of auripyrones have been reported.399–402
Dolabelide A (59a; Fig. 16; Table II) and its acetyl derivative dolabelide B (59b; Fig. 16;
Table II) are C-22 macrolides isolated from Japanese specimens of D. auricularia (Fig. 1D;
Table I).403 Their GI50 values were 8 and 2 μM, respectively, in human HeLaS3 cervix
cancer cells.403 Dolabelides C (59c; Fig. 16; Table II) and D (59d; Fig. 16; Table II) were
also isolated from Japanese specimens of D. auricularia, with GI50 values of 2 μM for both
compounds in the HeLaS3 cancer cell line.404 Various chemical syntheses of dolabelides have
been reported.405,406
Ulapualide A (60a; Fig. 17; Table II) and ulapualide B (60b; Fig. 17; Table II) were
isolated from the red-colored egg masses of the nudibranchHexabranchus sanguineus (Fig. 1G;
Table 3).407 Though exposed and vulnerable, these eggs have only one known predator, the
aeolid nudibranch Favorinus japonicus.407 Ulapualides A and B could be some of the bioactive
metabolites protecting these eggs from their predators.407 Ulapualide A can also be found in
sponges.408 Ulapualides contain in their structures three contiguous oxazole rings, forming
part of a macrolide ring with the attached lipid-like side chain that terminates in theN-methyl-
N-alkenylformamide group.407 The total synthesis of ulapualide A was reported in 1998.408
Ulapualides A and B displayed GI50 values of10 and30 nM, respectively, in murine L1210
leukemia cells.407 Ulapualide A harbors potent actin-depolymerizing activity.409
Another study on the egg masses of an unidentified nudibranch led to the characterization
of kabiramide C (61a; Fig. 17; Table II), which contains a macrolide ring possessing contiguous
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Figure 16. Chemical structures of aurisides A (56a) and B (56b), dolastatin 19 (57), auripyrones A (58a) and B
(58b), and dolabelides A (59a), B (59b), C (59c), and D (59d).
trisoxazole rings.410 Compound 61a was later isolated from the nudibranch H. sanguineus
(Fig. 1G; Table I) and from two Halichondria sponges.411 More recently, kabiramide C was
found along with other kabiramides, including kabiramide G (61b; Fig. 17; Table II), in the
sponge Pachastrissa nux.412 Kabiramide C displays in vitro growth inhibitory effects that are
tenfold higher in humanMCF-7 breast cancer cells (GI50 =0.5μM) than in humanfibroblasts
(GI50 = 8 μM).412 This compound thus appears to display a certain level of bioselectivity.
The bioselectivity of kabiramide G is even more pronounced with GI50 values of 0.02 μM in
MCF-7 cancer cells and >2 μM in human fibroblasts.412 Kabiramide C binds to actin and its
actin complex, which is formed through a two-step binding reaction, is extremely stable, and
long-lived.413 Although kabiramide C binds to actin, it nevertheless displays a certain level of
bioselectivity between normal and cancer cells as mentioned above.412
Some years later, Matsunaga et al.414 isolated a series of new kabiramides (Table II) in-
cluding A (61c; Fig. 17), B (61d; Fig. 17), D (61e; Fig. 17), and E (61f; Fig. 17), as well as
Medicinal Research Reviews DOI 10.1002/med
MARINE MOLLUSK-DERIVED AGENTS WITH ANTIPROLIFERATIVE ACTIVITY  747
Figure 17. Chemical structures of ulapualides A (60a) and B (60b), and kabiramides C (61a), G (61b), A (61c),
B (61d), D (61e), and E (61f).
dihydrohalichondramide (62a; Fig. 18) and 33-methylhalichondramide (62b; Fig. 18; Table II
under halichondramides) from the egg masses of H. sanguineus (Fig. 1G; Table I).414 Hali-
chondramide (62c; Fig. 18) was isolated from the spongeHalichondria sp. collected in Palau.415
Dalisay et al.416 report that H. sanguineus is a specialist predator with a spongeverous diet:
in an aquarium, the nudibranch was found to consume only Halichondria containing trisoxa-
zole macrolides and not sponges of other species or genera. Dalisay et al.416 thus argue that
these observations provide strong evidence that H. sanguineus acquires its suite of trisoxazole
macrolides from a selective sponge diet.
Dihydrohalichondramide and 33-methylhalichondramide displayed growth inhibitory ef-
fects in themurineL1210 leukemia cell linewithGI50 values of40 and60 nM, respectively.414
Kabiramides A and B were active with GI50 values of10 nM, and kabiramides D and E with
GI50 values of 30 nM in the same cancer cell line.414 Halichondramide and dihydrohalichon-
dramide disrupt actin microfilaments.417 Halichondramide displays the GI50 value of<1μM in
human PC-3 prostate cancer cells.418 This compound is cytostatic at low (0.5 μM) and cyto-
toxic at higher concentrations (2.5 μM).418 Halichondramide displays both antiproliferative
and antimigratory effects in vitro. It induces A549 (NSCLC) cell cycle arrest in the G/2 phase
with upregulation of p53 and GADD45α and downregulation of cyclin B1, cyclin A, CDC2,
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Figure 18. Chemical structures of dihydrohalichondramide (62a), 33-methylhalichondramide (62b),
halichondramide (62c), laulimalide (63a) isolaulimalide (63b), and 3-acetyl-11-(3-methylbutanoyl)-13-
propanoylilikonapyrone (65).
and CDC25C.419 The growth inhibitory effects induced by halichondramide in A549 NSCLC
cancer cells were also associated with the suppression of mTOR and its downstream effector
4EBP1 and p70S6K; this process occurs by its effects on the regulation of mTOR upstream
proteins, such as downregulation of Akt and p38 MAPK, and also upregulation of AMPK.419
As alreadymentioned previously, the A549NSCLC cell line displays various levels of resistance
to proapoptotic stimuli.351 In terms of antimigratory effects observed in vitro, halichondramide
suppresses the expression of a potential metastatic biomarker, phosphatase of regenerating
liver-3 (PRL-3), in human PC-3 prostate cancer cells.418 The suppression of PRL-3 sequentially
downregulates the expression of phosphoinositide 3-kinase (PI3K) subunits p85 and p110.418
The antimigratory (antimetastatic) effects induced by this compound in PC-3 cancer cells were
also correlated with the downregulation of matrix metalloproteases (MMPs) and the mod-
ulation of cadherin switches, N-cadherin and E-cadherin.418 It is unfortunate that although
halichondramide (NSC622258) exists in the NCI database, no data are available.
Laulimalide (63a; Fig. 18; Table II) and isolaulimalide (63b; Fig. 18; Table II) aremacrolides
that were isolated from the Indonesian sponge Hyattella sp. and its nudibranch predator,
Chromodoris lochi (Table I).420 Laulimalide displays growth inhibitory activity in lownanomolar
ranges in about a dozen of cancer cell lines,420,421 while isolaulimalide is much less potent
with GI50 values in low micromolar range.422 Laulimalide is active in P-gp overexpressing
cancer cells421,423 and against cell lines resistant to paclitaxel or epothilones.423 It has a unique
binding site located on two adjacent β-tubulin units between tubulin protofilaments of a
microtubule.212,424 In addition, although laulimalide is a microtubule stabilizer as are the plant-
derived metabolites taccalonolide and paclitaxel, laulimalide causes the formation of aberrant,
but structurally distinct mitotic spindles in contrast to the effects induced by the other two
molecules.425 Kanakkanthara et al.426 showed that increased expression of βII- and βIII-
tubulin isotypes in ovarian cancer cells confers resistance to laulimalide.426 Downregulation of
vimentin (an intermediate filament) expression in human ovarian carcinoma cells also confers
resistance to laulimalide.427
Liu et al.421 evaluated the in vivo anticancer activity of laulimalide in two xenograft models,
humanMDA-MB-435 breast cancer and the humanHT-1080 fibrosarcomamodels. They found
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Figure 19. Chemical structures of aplyronines A (64a), B (64b) and C (64c), D (64d), E (64e), F (64f), G (64g),
and H (64h), and of sphinxolide (66).
only minimal tumor growth inhibition; rather, severe toxicity accompanied by mortality was
observed. In contrast, paclitaxel (positive control) led to the clear anddramatic tumor regression
in both studies, without unacceptable toxicities.421 Various teams are actively involved in the
syntheses of various fragments of the laulimalide structure with the goal of reaching an efficient
total synthesis of this compound.428–433
An investigation of the chemical composition ofA. kurodai (Table I) led to the isolation and
characterization of the macrolide family named aplyronines (Table II), specifically aplyronine
A (64a; Fig. 19), B (64b; Fig. 19), C (64c; Fig. 19), D (64d; Fig. 19), E (64e; Fig. 19), F (64f;
Fig. 19), G (64g; Fig. 19), and H (64h; Fig. 19).434–437 Yamada et al.438 and Kita and Kigoshi439
reviewed the chemical and pharmacological characteristics of aplyronine A and its analogues.
The GI50 values were 0.08, 0.5, 3, 10, and 22 nM for aplyronine D, A, B, H, and C,
respectively, in the study by Ojika et al.,437 who used human HeLa-S3 cancer cells. Yamada
et al.434 found GI50 values of 0.4 nM for aplyronine A, 4 nM for aplyronine B, and 20
nM for aplyronine C, respectively. The presence of various methylated amino acids (N,N,O-
trimethylserine orN,N-dimethylalanine) at the position 22 seems to influence the in vitro growth
inhibitory activity of these macrolides.437 Aplyronine A is registered as NSC687160 in the NCI
database and it displays the mean GI50 value in the 60 cancer cell line panel of0.2 nM. While
highly effective against cancer cells in terms of growth inhibition, it is interesting to note that
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aplyronine A does not inhibit the 60 cancer cell lines in a homogeneous manner, but rather
displays some selectivity toward certain cell lines (but not toward a given histopathological
group). Indeed, six cancer cell lines, specificallyHOP-92 (NSCLC), OVCAR-4 (ovarian cancer),
TK-10 and UO-31 (renal cancer), and BT-549 and T47-D (breast cancer) display GI50 values
that are 10- to 100-fold higher than the mean GI50, indicating that these six cancer cell lines
are 10- to 100-fold more resistant to aplyronine A. In sharp contrast, the MDR cancer cell line
NCI/ADR-RES displays a GI50 concentration of0.2 nM, indicating that aplyronine A is not
a substrate for the P-gp efflux pump. Thus, aplyronineA does not behave in vitro as a nonspecific
poisonous agent. In addition, aplyronine A displayed high in vivo anticancer activity (without
obvious limiting toxicity) in various murine syngeneic tumor models, including P388 leukemia,
Lewis lung carcinoma, Erhlich carcinoma, colon 26 carcinoma, and B16 melanoma.434 The
increases in life span ranged between 201% (B16 melanoma model) and 556% (Lewis lung
carcinoma).434 Thus, the life spans of the aplyronine A-treated tumor-bearing mice increased
by twofold to more than fivefold as compared to those of the control (untreated) tumor-bearing
mice. To our surprise, we did not find any reports describing aplyronine A’s in vivo anticancer
effects in human xenograft models.
We ran a COMPARE analysis for aplyronine A in the standard agent dataset of the NCI
database and found p = 0.62 as a correlation with vincristine sulfate, p = 0.70 with maytansine
and 0.87 with vinblastine sulfate. These three compounds are well-known tubulin inhibitors and
both vincristine and vinblastine are routinely used to treat cancer patients whose cancer belongs
to various histopathological types.Ado-trastuzumab emtansine (T-DM1) is a human epidermal
growth factor receptor 2 (HER2) targeted antibody–drug conjugate composed of trastuzumab,
a stable linker (4-(N-maleimidomethyl)cyclohexane-1-carboxylate, MCC), and the cytotoxic
agent DM1, which is mertansine, a derivative of maytansine.440 T-DM1 underwent several
successful Phase III clinical trials and it is now proposed as a treatment of choice in second line
and beyond for patients with advanced HER2-expressing breast cancer.440
Aplyronine A was proposed recently as an inhibitor of the actin microfilaments. Hirata
et al.441 reported that aplyronine A depolymerizes F-actin and inhibits the polymerization
of actin by forming a 1:1 complex with monomeric actin. These authors441 concluded that,
indeed, as expected, aplyronine A binds to a hydrophobic cleft composed of subdomains
1 and 3 of actin by intercalating its aliphatic tail into the actin molecule as do the other
reported F-actin depolymerizing agents. Kita et al.,442 after comparing the amount of abundant
actin molecules with the amount of aplyronine A incorporated into the cells, came to the
conclusion that the significant antitumor activities of this compound may not be accounted
for only by its F-actin-severing properties. They elegantly demonstrated recently that, in fact,
aplyronine A forms a 1:1:1 heterotrimeric complex with actin and tubulin and inhibits tubulin
polymerization. Kita et al.443 thus emphasize that aplyronine A represents a rare type of natural
product that binds to two different cytoplasmic proteins to exert its highly potent anticancer
activities.
Aplyronine A was reported to exert proapoptotic effects in cancer cells.444 However, these
data have been obtained in cancer cells that display very high sensitivity to proapoptotic stimuli
(HL-60 leukemia and HeLa cervix carcinoma). In addition, the fact that this compound could
induce proapoptotic effects in some cancer cell type is the logical consequence (and not at all
a cause) of cell death occurring when crucial components such as microfilaments (actin) and
microtubules (tubulin) are severely damaged by a given compound.
The impressive in vivo anticancer activity observed by Yamada et al.434 in five distinct
murine tumor models, as reported above, was obtained with doses ranging from 0.04 to
0.08 mg/kg. Several strategies are already underway to obtain aplyronine A by means of
chemical syntheses.445,446 Paterson et al.447,448 claimed that aplyronine A has potential as a
clinical candidate. However, the in vivo data reported by Yamada et al.434 have never been
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replicated, even though gram quantities of aplyronine A are currently available. The clinical
trial site, https://clinicaltrials.gov, does not mention any ongoing trial with aplyronine A.
A lipophilic extract of the pulmonate mollusk Onchidium sp.2 (Fig. 1I; Table I) collected
from the South China Sea contained a series of polypropionates characterized by the pres-
ence of bis-γ -pyrone rings and structurally related to ilikonapyrones, previously found in a
different species of pulmonate.449 The in vitro growth inhibition assay carried out on the
metabolites isolated from this mollusk showed growth inhibitory activity for only 3-acetyl-
11-(3-methylbutanoyl)-13-propanoylilikonapyrone (65; Fig. 18; Table II) in a minipanel of six
human cancer cell lines: A549 NSCLC, MCF-7 breast cancer, PC-3 prostate cancer, Hs683
oligodendroglioma, U373 glioblastoma, and SKMEL-28 melanoma.449 The GI50 values were
very similar and ranged from 3 to 9 μM, without any correlation with the level of sensitivity of
these cancer cell lines to proapoptotic stimuli, indicating therefore that this metabolite is active
against cancer cells displaying resistance to proapoptotic stimuli.449
Sphinxolides bear structural resemblance to scytophycins, which are found in cyanobac-
teria, such as Scytonema pseudohofmanni.447,450 Sphinxolide (66; Fig. 19; Table II) is a 26-
memberedmacrolide that was first isolated from an unidentified Pacific nudibranch451 and later
reisolated from the New Caledonian marine sponges Neosiphonia superstes and Reidispongia
coreula, along with the congeneric reidispongiolides.452,453
Like the related families of trisoxazole-containing marine macrolides (described above),
sphinxolide is an actin-binding molecule that disrupts the actin microfilament organization.447
As previously mentioned and clearly emphasized by Paterson et al.447 and Allingham et al.,454
actin microfilaments exert crucial roles in cancer cell division and metastasis and therefore
actin-binding natural products could be used as leads for novel types of cancer chemotherapy.
However, the actin microfilaments also exert crucial roles (as microtubules) on eukaryotic cell
shape, cell motility, cell adhesion, and intracellular transportation.447,454 Antiactin compounds
seem at first glance more toxic than antitubulin ones if one takes into account that no antiactin
compound is currently marketed as an anticancer drug.
Sphinxolide displays in vitro GI50 value of 0.02 nM in human KB cancer cells.451 The
actin-binding properties of sphinxolide in cancer cells lead to subsequent apoptosis,450 as usually
occurs with any compounds severely impairing the microfilament and/or the microtubule
networks. Sphinxolide causes rapid loss of microfilaments in cultured cells, without affecting
microtubule organization, and potently inhibits actin polymerization in vitro as well as the
microfilament-dependent ATPase activity of purified actomyosin, indicating the direct effect
on actin.450 It is active in vitro against MDR cancer cells.450,454 No in vivo studies have been
performed for sphinxolide, at least to the best of our knowledge, and it is not registered in the
NCI database.
Latrunculins A (67a; Fig. 20; Table II) and B (67b; Fig. 21; Table II) were first reported
as spongian metabolites, but were subsequently isolated from different dorid mollusks. In
particular, Glossodoris quadricolor (also named Chromodoris quadricolor; Fig. 1F; Table I)
accumulates latrunculin B from Latrunculia magnifica,455 whereas latrunculins A was found
in C. lochi feeding on Spongia mycifijensis.456 In addition to C. lochi, compound 67a has been
recently also found in other four species belonging to the genusChromodoris:C. elisabethina,C.
kuiteri, C. annae, and C. magnifica, showing that it acts as both a feeding deterrent and a toxic
chemical weapon.189 These diet-derived toxins are characterized as 2-thiazolidinonemacrolides
and were shown to be strongly ichthyotoxic and cytotoxic.457 Latrunculin A displayed GI50
values of0.5 μM in the study by Longley et al.,458 who utilized three cancer cell lines: murine
P388 leukemia, and human HT-29 colon cancer, and A549 NSCLC.458 Although the P388
leukemia cells115,317 are much more sensitive to proapoptotic stimuli than the A549 NSCLC
ones,351 latrunculin A displayed greater than a fivefold level of in vitro growth inhibitory
effects against A549 NSCLC compared to P388 leukemia.458 It thus seems that the marked
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Figure 20. Chemical structures of latrunculins A (67a) and B (67b), kelletins I (68a) and II (68b),
hydroxyl-dehydroisofulvinol (69a), fulvinol (69b), aplaminal (70), aplaminone (71a), neoaplaminone (71b), and
neoaplaminone sulfate (71c).
Figure 21. Chemical structures of isofistularin-3 (72), and malyngamides O (73a), S (73b), and X (73c).
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latrunculin’s A growth inhibitory effects are not impaired by the levels of resistance of cancer
cells to proapoptotic stimuli. Latrunculin A is registered in the NCI database as NSC613011.
Its mean GI50 value in the 60 cancer cell line panel is0.7 μM, and there is more than twofold
log magnitude difference between the most sensitive and the most resistant cancer cell lines.
Latrunculin A thus does not behave as a nonspecific poison. In addition, this compound is
as active against MDR NCI/ADR-RES as it is against cells that do not display the MDR
phenotype.
The in vitro growth inhibitory effects of latrunculins, including latrunculin A are related
to their ability to reversibly bind actin monomers, forming 1:1 stoichiometric complexes with
G-actin, and therefore disrupting actin polymerization.459,460 As expected with antitubulin
and/or antiactin compounds, apoptosis occurs in latrunculin A treated cancer cells. Konishi
et al.461 showed that latrunculin A induced apoptosis in cancer cells occurs via the activation of
the caspase-3/caspase-7 pathway. We ran a COMPARE analysis on latrunculin A and found
no correlation with p  0.7 with compounds in the standard agent database.
Konishi et al.461 report that latrunculinA has strong anticancer effects in peritoneal dissem-
ination models of MKN45 and NUGC-4 human gastric cancer in mice. The in vivo anticancer
activity of latrunculin A was also evaluated in s.c. A549 NSCLC xenografts in which this com-
pound increased by 46% the life span of the treated tumor-bearing mice as compared to the
control.458
The prosobranch Kelletia kelletii is a hard-shelled mollusk (Table I) that contained among
other compounds kelletinins I (68a; Fig. 20; Table II) and II (68b; Fig. 20; Table II), p-OH-
benzoic acid tetraester of erithritol, and 2-deoxy-D-ribose, respectively. The two compounds
displayed in vitro growth inhibitory effects with GI50 values of 0.07 μM in murine L1210
leukemia cells.462
Peltodoris atromaculata (Fig. 1J, Table I) is aMediterranean nudibranch usually feeding on
sponges of genus Petrosia, whose secondary metabolites are mainly long-chain polyacetylenes
called petroformynes.463 This mollusk sequesters the sponge metabolites and accumulates them
in their digestive glands.463 No reports about in vitro growth inhibitory effects against cancer
cells have yet been published for this type of compounds, at least to the best of our knowl-
edge. However, petroformynes strongly resemble related compounds from sponges, neopetro-
formynes, which display GI50 values ranging between 0.1 and 0.7 μM in murine P388 leukemia
cells.464 Recently, a recollection of the same animal feeding on the spongeHaliclona fulva led to
the isolation of new polyacetylenes, including hydroxyl-dehydroisofulvinol (69a; Fig. 20; Table
II), which resembles fulvinol (69b; Fig. 20). Fulvinol (69b), isolated from the sponge Reniera
fulva, displays a mean GI50 value of 2 μM in four cancer cell lines: murine P388 leukemia,
A549 NSCLC, HT-29 colon cancer, and SKMEL-28.465 Hydroxyl-dehydroisofulvinol, iso-
lated from P. atromaculata, displayed a GI50 value of 3 μM against SKMEL28 melanoma
cells.466
4. Nitrogen Containing Compounds
Kuroda and Kigoshi467 isolated aplaminal (70; Fig. 20; Table II), containing a triazabicyclo
[3.2.1] octane framework from A. kurodai. This compound displays a GI50 value of 2 μM
against human HeLaS3 cervix carcinoma cells.467
Aplaminone (71a; Fig. 20; Table II), neoaplaminone (71b; Fig. 20; Table II), and
neoaplaminone sulfate (71c; Fig. 20; Table II) were also isolated from Japanese specimens ofA.
kurodai.468 From the chemical perspective, these substances are constructed from a bromine-
containing dopamine unit and a sesquiterpenoid part.468 Aplaminone and neoaplaminone
sulfate display GI50 values of 1 μM against human HeLa cervix cancer cells, while
neoaplaminone has the GI50 of 1 nM in this cancer cell line.468
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Figure 22. Chemical structures of dolabellin (74), hectochlorin (75a) and its deacetylated form (75b), lamellarin
D (76), staurosporine analogues (77a, 77b), and tambjamines D (78a), E (78b), and K (78c).
Tylodina perversa is a Mediterranean notaspidean mollusk whose dietary preference are
sponges of genus Aplysina.469,470 Brominated isoxazoline alkaloids constitute the metabolite
pattern of these porifera with validated feeding deterrent properties against fishes.470 Studies
in natural and captivity conditions showed that T. perversa is able to sequester and accumulate
these metabolites in different anatomical parts.470 Among all isoxazoline alkaloids found in
this mollusk, isofistularin-3 (72; Fig. 21; Table II) displayed the GI50 value of 9 μM against
human HeLa cervix carcinoma cells.470
Malyngamides are N-substituted amides of long chain methoxylated fatty acids, charac-
terized by the presence of a trans double bond and a 7S configuration of the oxygen-bearing
carbon. To date, more than 30 malyngamides have been isolated from cyanobacteria and
sea hares. Metabolites of this class have been reported to possess in vitro growth inhibitory
properties against cancer cells and include malyngamide O (73a; Fig. 21; Table II), isolated
from the anaspidean mollusk Stylocheilus longicauda,471 as well as malyngamide S472 (73b;
Fig. 21; Table II) and malyndamide X473 (73c; Fig. 21; Table II), both isolated from Bur-
satella leachii (Table I). These three compounds displayed GI50 values ranging between 4
and 8 μM in seven cancer cell lines including murine P388 leukemia and human A549
NSCLC, NCI-H187 (SCLC), HT-29 colon cancer, HL60 leukemia, KB and BC breast cancer
models.471–473
An investigation of Indian Ocean specimens of the sea hareD. auricularia (Fig. 1D, Table I)
led to the isolation of a bisthiazole metabolite, dolabellin (74; Fig. 22; Table II), which displayed
the GI50 value of 10 μM in the human HeLaS3 cervix carcinoma cell line.474
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Although previously isolated from the cyanobacterium L. majuscula, hectochlorin (75a;
Fig. 22; Table II) and its deacetylated derivative (75b; Fig. 22; Table II) have also been found
in the sea hare B. leachii (Fig. 1C, Table I).475 Hectochlorin structurally resembles dolabellin
(74, Fig. 22) as reported by Marquez et al.476 In the study by Suntornchashwej et al.,475 the in
vitro growth inhibitory effects of compounds 75a and 75b were determined in the human KB,
NCI-H187 SCLCL, and BC breast cancer cell lines. The deacetylated derivative of hectochlorin
75b was the most active of these two compounds, displaying a mean GI50 value of 1 μM.475
Marquez et al.476 showed that hectochlorin is equipotent to jasplakinolide in its ability to pro-
mote actin polymerization, however unlike jasplakinolide, it is unable to displace a fluorescent
phalloidin analogue from polymerized actin. Hectochlorin has no effect on the polymerization
of purified tubulin.476
Marquez et al.476 also report that hectochlorin displays a unique profile in the NCI 60
cancer cell line panel. Indeed, it showed the greatest potency against several cell lines in the
colon, melanoma, ovarian, and renal cell line panel with the average GI50 against the 60 cell line
panel of 5 μM.476 In addition, the flat shape of the dose–response curves of heterochlorin is
generally characteristic of compounds that are cytostatic rather than cytotoxic.476 The chemical
total synthesis of hectochlorin has been reported by Cetusic et al.477
More than three decades ago,Andersen and et al.478 isolated lamellarins, aromatic alkaloids
characterized by the presence of a fused-pyrrole ring, from the Palauan prosobranch mollusk
Lamellaria sp. various. Since the first report, more than 50 lamellarins have been found mainly
inDidemnum spp. ascidians as well as in various sponges.479–481 Of all the lamellarins identified
up to date, lamellarin D (76; Fig. 22; Table II) displays the highest growth inhibitory effects
on cancer cells,481 with GI50 values ranging between 10 and 20 nM in a large panel of cancer
cell lines.478 In addition to the nuclear targeting involving topoisomerase I inhibition with the
modulation of several apoptotic mediators,482,483 lamellarin D accumulates rapidly inside the
mitochondria, directly poisoning themitochondrial topoisomerase I (Top1mt), and thus leading
to the dysfunctional mitochondrial respiration in cells.484,485 As suggested by the sensitivity of
topoisomerase I mutated P388-CPT5 chemoresistant cells,482 lamellarin’s D dual mechanism
may be effective against drug-resistant cancers offering an alternative to the conventional
topoisomerase I inhibitors, irinotecan, and topotecan,which are inefficient asTop1mt inhibitors
due to their inactivation in the mitochondrial pH environment.486 In addition, lamellarin D is
not sensitive to P-gp and its growth inhibitory effects are maintained in MDR cancer cells.487
Due to its intriguing anticancer properties, lamellarin D has been the focus of considerable
research and several syntheses and SAR studies of lamellarin derivatives have been reported
in the last few years.481 The fact nevertheless remains that despite this research activity, no
in vivo efficacy has been demonstrated yet for lamellarins in general and for lamellarin D
in particular, at least to the best of our knowledge. A bioguided fractionation of various
extracts of the prosobranch mollusk Coriocella nigra resulted in the isolation of two members
of the staurosporine488 (selective kinase inhibitor) family: compounds 77a (4’-N-demethyl-
11-hydroxystaurosporine; Fig. 22; Table II under staurosporine analogues) and 77b (3,11-
dihydroxystaurosporine; Fig. 22; Table II).489 Their GI50 values in a minipanel of cancer cell
lines ranged between 4 and 130 nM.489
Tambjamines are methoxypyrrolic alkaloids whose chemical features resemble the bac-
terial prodigiosins.490–492 All these compounds contain a common 4-methoxy-2,2’-bipyrrole
chromophore.491,492 Tambjamines A–D (tambjamine D; 78a; Fig. 22; Table II) were iso-
lated from the nembrothid nudibranchs Roboastra tigris, Tambja eliora, and Tambja abdere
(Table I).490 Roboastra tigris is a large carnivorous nudibranch that preys on two smaller nudi-
branchs, T. eliora and T. abdere.490 Tambjamines A–D were also traced to a dietary source,
the ectoproct (bryozoan) Sessibugula translucens, and are implicated in a chemical defense
mechanism.490 Indeed, when attacked by R. tigris, T. abdere produces a yellow mucus from
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goblet cells in the skin and this defense secretion often causes R. tigris to break off its attack.490
Tambja eliora does not produce a defensive secretion but attempts to escape from R. tigris by
using a vigorous writhing motion.490 In laboratory experiments, R. tigris prefers to eat T. eliora
rather than T. abdere.490 Tambjamines E (78b; Fig. 22; Table II), F, G, H, I and J were isolated
from various bacteria and marine invertebrates.492 Tambjamine K (78c; Fig. 22; Table II) was
isolated from the Azorean nudibranch Tambja ceutae.493
The GI50 values of tambjamine K (78c) were determined in four cancer cell lines and
ranged between 0.004 and 15 μM.493 Tambjamine K displayed the GI50 value of 19 μM
in mouse 3T3-L1 fibroblasts.493 At first glance, it thus appears that tambjamine K (78c) is not
a bioselective compound. However, it displays a 4000-fold differential sensitivity between
human Caco-2 colon cancer cells and HeLa cervix cancer cells.493 Tambjamine K (78c) has
unfortunately not been assayed by the NCI.
Tambjamine C has recently been demonstrated to be an efficient anion carrier, that is,
a transmembrane anion transporter similar to prodigiosin, whereas tambjamine E does not
share this property and tambjamine K has not yet been assayed as such, at least to the best
of our knowledge.494 Transmembrane anion transporters play important roles in cancer cell
biology, including cancer cell migration, and they are distinctly expressed in various cancer cell
types.495–499 It is interesting to note that Caco-2 colon cancer cells, displaying high sensitivity
to tambjamine K as mentioned above, have often been used to study the roles of various
transmembrane transporters.500,501 Tambjamine E targets DNA as also does tambjamine D,502
which in addition displays genotoxic effects in normal cells.503 It thus appears that tambjamine
Kcertainlymerits additional in depth pharmacological and toxicological preclinical evaluations
as a potential anticancer agent.
A chemical investigation of theAsianmolluskTurbo stenogyrus (Table I) led to the isolation
of four cerebrosides, turbostatins A–D, whose GI50 values ranged between0.2 and4 μM in
murine and human cancer cell lines.504 The chemical structure of turbostatin A (79; Table II) is
illustrated in Figure 23.
Bathymodiolamides A (80a; Fig. 23; Table II) and B (80b; Fig. 23; Table II) are ceramides
isolated from the deep vent mussel Bathymodiolus thermophilus (Table I). Their GI50 values in
human HeLa cervix cancer and MCF7 breast cancer cells were <1 μM.505
Tyrindoleninone (81; Fig. 23; Table II) is a brominated indole derivative (6-bromo-2-
methylthioindolin-3-one) isolated from the egg mass extract of the gastropod Dicathais orbita
(Table I).506 The GI50 values of this compound in human colon cancer cells are >100μM.506
A series of pentacyclic alkaloids have been isolated from the prosobranchmolluskChelyno-
tus semperi (Table I) and its prey, an unidentified colonial tunicate.507 Among these compounds,
only kuanoniamine A (82; Fig. 23; Table II) showed weak growth inhibitory activity against
KB cancer cells (GI50 = 4 μM).507
The indole alkaloids phidianidines A (83a; Fig. 23; Table II) and B (83b; Fig. 23; Table II)
were isolated from Phidiana militaris (Fig. 1K; Table I), an aeolid nudibranch from the South
China Sea.508 The GI50 values for these compounds range between 0.4 and >100 μM in
three cancer cell lines. They display no bioselectivity toward mouse 3T3-L1 fibroblasts and
rat H9c2 cardiomyocytes as the GI50 values toward these cells ranged between 0.1 and 5
μM.508 Interestingly, while human HeLa cervix cancer cells display weak sensitivity to the
growth inhibitory effects of tambjamine K,493 they are much more sensitive to the growth
inhibitory effects of phidianidines.508 The exactly opposite features are observed with respect
to Caco-2 colon cancer cells.493 These data thus highlight distinct mechanisms of action for
tambjamine K and phidianidines A and B as potential anticancer compounds and suggest that
tambjamine K as well as phidianidines A and B are not nonspecific poisons. It would be very
interesting to have an NCI profiling of these compounds. Phidianidines A and B act as selective
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Figure 23. Chemical structures of turbostatin A (79), bathymodiolamides A (80a) and B (80b), tyrindoleninone
(81), kuanoniamine A (82), and phidianidines A (83a) and B (83b).
and potent ligands with partial agonist activity against the μ opiod receptor (versus δ- and
κ-opiod receptors).509 Indeed, the μ opiod receptor is involved in cancer progression.510 They
were also demonstrated to act as ligands of CXCR4, a chemokine receptor involved in cancer
progression and the metastatic process.511 Total syntheses of phidianidines A and B have been
reported.509,512–514
Fontana et al.515 isolated jorumycin (84a; Fig. 24; Table II) from the mantle and mucus of
the Pacific nudibranch mollusk, Jorunna funebris (Fig. 1H; Table I). Jorumycin displays GI50
values in low nanomolar or even subnanomolar ranges in various cancer cells including cells
resistant to proapoptotic stimuli.515,516 The high potency of jorumycin and the clinical successes
of ecteinascidin led to intensive chemical modifications of jorumycin’s chemical structure and
this campaign thus resulted in PM00104 (Zalypsis R©, 84b, Fig. 24).516 Petek and Jones516 recently
reviewed the preclinical and clinical data related to PM00104, which has entered several ongoing
Phase II clinical trials.
Jorumycin belongs to the class of dimeric isoquinoline alkaloids and it shares the same car-
bon framework as saframycin and ecteinascidin.515 In fact, ecteinascidin (trabectedin) has three
isoquinolines, while the other two alkaloids have only two isoquinolines per molecule, while
the two isoquinolines are joined in similar manner in all three compounds.515 The difference
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Figure 24. Chemical structures of jorumycin (84a), PM00104 (Zalypsis R©, 84b), jorunnamycin C (85), renier-
amycin M (86), and ES-285 (spisulosine, 87).
in structure between ecteinascidin and the jorumycin analog PM00104 could explain, at least
partly, why these two drugs display slightly different DNA-binding properties and nucleotide
excision repair dependencies.516
In 2007, studies on Thai J. funebris (Fig. 1H) specimens led to the isolation from the
mantle, viscera, and egg-ribbons novel tetrahydroisoquinoline alkaloids, jorunnamycins A–C,
along with several renieramycins.517 It is interesting to note that certain renieramycins have
also been isolated from the Thai sponge Xestospongia sp.518 Indeed, J. funebris is carnivorous
and feeds mainly on sponges such a Xestospongia sp., Haliclona sp., Euplacella cf. australis,
and Oceanapia sp.517 Jorunnamycin C (85; Fig. 24; Table II) and renieramycin M (86, Fig. 24,
Table II) differ only in the C-22 ester side chain. These two compounds display GI50 values in
the low nanomolar ranges against human colon (HCT-116) and breast (MDA-MB-435) cancer
cells.518 Charupant et al.518 showed that the downregulation of protein tyrosine phosphatase
receptor type K (PTPRK) could be one of the pathways through which jorunnamycin C (85)
and renieramycin M (86) exert their anticancer effects, at least in vitro. PTPRK acts as a tumor
suppressor gene product519 and could be implicated in the progression of colon cancer.520
Sphingolipid-related compounds called spisulosines were isolated from the Nord-Atlantic
clam Spisula polynyma (syn. Mactromeris polynima; Table I).521,522 Sphingolipids constitute
a group of natural products characterized by the presence of a long chain 2-amino-1,3-diol
scaffold or sphingoid base.522 As emphasized by Abad et al.,522 besides playing a structural
role and regulating the physical properties of cell membranes, sphingolipid metabolites also
participate in cell signaling and in the control of numerous cellular functions in mammals.
Spisulosines constitute a group of 1-deoxysphingolipids derived from a central core lacking
the C1-OH group present in dihydrosphingosine.522 One of these spisulosines is ES-285 (87;
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Fig. 24; Table II under Spisulosine), which resembles the natural sphingolipids in the C18
sphingoid backbone and in the (2S,3R) configuration of the amino and hydroxyl groups,
respectively.522 ES-285 is associated with GI50 values ranging between low nanomolar and low
micromolar in the NCI 60 cancer cell line panel.522–526 ES-285 triggers an atypical cell death
pathway because it does not affect pathways widely implicated in regulating cell survival and
apoptosis, such as JNK, ERKs, or Akt, but it nevertheless activates caspase-3 and caspase-
12.525 Sa´nchez et al.526 showed that ES-285 inhibits the growth of human PC-3 and LNCaP
prostate cancer cells through intracellular ceramide accumulation and PKCzeta activation.
This compound modulates RHO protein and ceramide signaling and consequently induces
disassembly of the actin stress fibers,527 but does not affect the microtubule network.525
ES-285 is COMPARE-negative, suggesting therefore a possible novel mechanism of an-
ticancer action as compared to the other anticancer drugs.524 It displayed significant in vivo
anticancer activity in a hollow fiber model with s.c. implanted SK-HEP-1 hepatoma tumor
cells, and xenografted models utilizing human PC-3 prostate and MRI-H-121 renal cancer
cells.524 ES-285 has entered several Phase I clinical trials since the late 2000s. Baird et al.524
report that pharmacologically relevant concentrations of this drug were safely achieved in adult
cancer patients, with pharmacogenomics studies indicating changes in the expression of genes
of potential mechanistic relevance. Scho¨ffski et al.528 reported hepato- and neurotoxicity as
schedule independent dose-limiting adverse events for ES-285 were noted. Vilar et al.529 also
observed liver enzyme elevations as dose limiting for ES-285 administration to cancer patients.
Massard et al.530 also recently conducted a Phase I clinical trial. To the best of our knowledge,
there is no available information on its Phase II clinical trials.
5. TARGETED DELIVERY OF MOLLUSK-DERIVED ANTICANCER AGENTS
Some of the issues that have prevented the advancement of mollusk-derived anticancer agents
to the clinic can be mitigated by employing delivery vehicles that can improve the drugs’ ability
to impart a strong therapeutic action while minimizing off-target effects. Nanomedicine, or the
medical application of nanotechnology, has been at the forefront of the anticancer drug deliv-
ery field. Nanomedicines are designed to improve the drug’s solubility in physiological fluids,
improve the drug’s biodistribution and pharmacokinetics, passively or actively target tumors,
and protect the drug from premature degradation or excretion. Nanomedicines including lipo-
somes, micelles, nanoparticles, nanoemulsions, nanocapsules, dendrimers, andmacromolecular
conjugates have been utilized to improve the performance of many anticancer agents.531 These
drug delivery systems can target tumors passively by taking advantage of the enhanced perme-
ability and retention (EPR) effect which is a result of the high permeability of leaky angiogenic
blood vessels and poor lymphatic function at the tumor.532,533 In addition, nanomedicines can
be actively directed to molecular targets overexpressed in tumors by inclusion of high affinity
ligands such as antibodies, aptamers, or peptides on their structure.532,534,535
Nanomedicines can utilize a number ofmaterials including biocompatible lipids, polyesters,
oligosaccharides, polyethers, oligonucleotides, peptides, and evenproteins.Among thesemateri-
als, the polyether poly(ethylene glycol) (PEG) has beenwidely used in drug delivery applications
due to its ability to shield hydrophobic biomaterials and increase the circulation time of macro-
molecules and nanocarriers.536 Nanomedicines can also include activatable switches that main-
tain the drug in an inactive, nontoxic state until activated by low pH, reducing conditions, or
proteolytic enzymes that are overexpressed in tumors.537 Nanomedicines can enable delivery of
high-drugpayloads andhavebeen reported toovercomeMDR.531 Several nanomedicine formu-
lations of anticancer agents including DoxilTM, MyocetTM, DaunoXomeTM, and AbraxaneTM
have been approved by the FDA for clinical use. Among the various types of nanomedicines,
Medicinal Research Reviews DOI 10.1002/med
760  CIAVATTA ET AL.
surprisingly only few types of nanovectors (namely micelles, nanoparticles, and conjugates)
have been explored with mollusk-derived anticancer agents. In all cases, these nanovectos were
used as means to increase the solubility of or to minimize dose-limiting toxicity associated with
these highly active anticancer agents by targeting tumors. Next, we summarize the reported
design as well as results of in vitro and in vivo evaluation, as available, of nanovectors utilized
for the targeted delivery of mollusk-derived anticancer agents.
A. Lamellarins
Macromolecular covalent conjugates of lamellarin D (76, Fig. 22; Table II) were prepared to
enhance the solubility of this hydrophobic alkaloid. A multiarm PEG dendrimer conjugate
of lamellarin D (88, Fig. 25) decreased the GI50 value of the drug by 40% in MDA-MB-231
breast cancer cells, but showed slightly higher GI50 in HT29 colon cancer cells and A549
lung cancer cells.538 On the other hand, a nuclear localization sequence (NSL) oligopeptide
conjugate of lamellarin D (89, Fig. 25) had lower GI50 values in all three cancer cell lines.538
Importantly, both conjugates 88 and 89 showed reduced growth inhibition in noncancerous
BJ skin fibroblasts, demonstrating bioselectivity of these drug delivery systems toward cancer
cells.538 in vivo evaluation of these conjugates has not been reported.
Lamellarin N (90, Fig. 25), a hydrophobic compound (logP= 3.37) isolated frommollusks
and later found in ascidians and sponges, was incorporated into polymeric micelles as a means
to improve its aqueous solubility. Biodegradable micelles are self-assembled nanostructures
made from amphiphilic block copolymers where the hydrophobic polymer segments form
an inner core in which hydrophobic drugs can be entrapped, and the hydrophilic segments
form a protective shell that interacts with the surrounding aqueous medium. Micelles of the
amphiphilic block copolymers poly(ethylene glycol)-b-poly(ε-caprolactone) (PEG-b-PCL) and
poly(ethylene glycol)-b-poly(D,L-lactide) (PEG-b-PLA) were used to encapsulate Lamellarin
N.539 Importantly, encapsulation increased the concentration of lamellarin N that could be
suspended in water by up to 200-fold compared to the free drug.539 Neither in vitro nor in vivo
evaluation of these micelles was reported.
B. Kahalalides
As previously mentioned, kahalalide F (15a, Fig. 6; Table II) is a depsipeptide that has been
evaluated in Phase II clinical trials for the treatment of melanoma, liver cancer, and NSCLC.
Unfortunately, these clinical trials failed to demonstrate anticancer response in patients. The
activity of two diastereomeric cysteine analogues of kahalalide F (91a and 91b, Fig. 26) conju-
gated to 20- and 40-nm gold nanoparticles was evaluated in vitro.540 The gold-drug nanoscaled
conjugate aimed to utilize the nanoparticles’ ability to deliver a high payload of the peptide
to the cells intracellularly, thereby increasing therapeutic efficacy. Studies in HeLa cervical
carcinoma cells showed that although the cell growth inhibition of the 20-nm gold nanopar-
ticle conjugates was not different than that of the free peptides, the 40-nm conjugates of 91a
and 91b resulted in higher cell growth inhibition.540 Similarly, higher nanoparticle uptake into
HeLa cells was observed with 40-nm nanoconjugates as demonstrated with confocal fluores-
cence microscopy.540 Neither in vitro nor in vivo therapeutic efficacy was evaluated with these
nanoparticle systems.
Elisidepsin (15b, Fig. 6), a cyclic peptide of kahalalideF, also failed clinical trials due to poor
therapeutic activity. An elisidepsin oral formulation based on 150-nm solid lipid nanoparticles
of Precirol R© ATO 5 was evaluated as a means to increase the oral bioavailability of this drug.541
This delivery system was evaluated in Beagle dogs and compared to a cyclodextrin-based
formulation.541 Despite not being able to increase oral elisidepsin bioavailability above 1%, the
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Figure 25. Chemical structures of multiarm PEG dendrimer of lamellarin D (88), nuclear localization sequence
oligopeptide conjugate of lamellarin D (89), and lamellarin N (90).
nanoparticle formulation enhanced drug absorption and maintained the drug concentration in
the blood within measurable levels over a longer timeframe than cyclodextrin.541 The in vivo
therapeutic efficacy of this oral delivery system was not reported.
C. Dolastatins
Several dolastatins have been formulated into antibody conjugates as a means to in-
crease their concentration at the tumors while minimizing off-target effects. The FDA-
approved monomethyl auristatin E (MMAE) conjugate with anti-CD30 antibody (brentux-
imab vedotin) has been approved for the treatment of Hodgkin’s lymphoma. As previously
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Figure 26. Chemical structures of D-cys (91a) and L-cys (91b) analogs of Kahalalide F that were conjugated to
gold nanoparticles for intracellular delivery.
mentioned, antibody–drug conjugates have been previously reviewed166,200,219,222 and will not
be further discussed in this review. Most nanomedicine systems for the delivery of dolastatins
have been developed for the highly potent and dose-limiting dolastatin 10 derivatives MMAE
(92, Fig. 27) and monomethyl auristatin F (MMAF, 93, Fig. 27). Here, we summarize cur-
rent efforts to develop innovative targeted and activatable auristatin nanomedicines that are
designed to protect healthy tissue from the drugs’ action while achieving high anticancer effect.
A folate-directed conjugate of MMAE (94, Fig. 27) based on a self-immolative linker that
could be activated by lysosomal β-galactosidase was developed by Legigan et al.542 in vitro tests
demonstrated over 20-fold higher growth inhibition by 94 in folate receptor-positive KB and
HeLa cells compared to folate receptor-negative A549 cells.542 Conjugate 94 also demonstrated
very high anticancer activity, with aGI50 of0.2 nM inKB cells. This systemwas not evaluated
in vivo.
Burns et al.543 demonstrated a pH-activated system for the delivery ofMMAEbased on pH
(low) insertion peptide (pHLIP) conjugates (95a and 95b, Fig. 27) that undergo conformational
changes under the acidic pH typical of tumors. Specifically, at a pHof6, the pHLIP conjugates
insert into the membrane and deliver their cargo directly into the cytoplasm of target cancer
cells. MMAE was conjugated to the C-terminus of wild type (95a) and modified (95b) pHLIP
via a disulfide bond that could undergo intracellular reduction for delivery of an N-modified
MMAE derivative.543 Studies with HeLa and MDA-MB-231 cancer cells demonstrated over
90% inhibition of cell growth after a 2-hr exposure to both drug conjugates.543 Conjugate
translocation and intracellular release of the drug occurred faster than passive diffusion of
free drug. Finally, cell growth inhibition with the conjugates was over 11-fold higher at pH
5.0 versus pH 7.4.543 A pilot in vivo study also showed that conjugate 97a was able to target
triple-negative MDA-MB-231 breast cancer xenografts in mice, although the in vivo antitumor
effect was not investigated.543
Batisse et al.544 developed delivery systems that targetedMMAE andMMAF to glycosph-
ingolipid globotriaosylceramide (Gb3, also referred to as CD77) positive cancer cells.544 The
systems consisted of degradable conjugates ofMMAEandMMAFand the cysteine-terminated
B-subunit of the Shiga toxin (STxB) (96 and 97, respectively, Fig. 27).544 The conjugates were
designed to enable release of the active agents under reducing conditions. 544 in vitro studies in
Gb3-positive and Gb3-negative HT29 colorectal cancer cells showed that the conjugates had
approximately 100-fold higher anticancer activity on Gb3-positive cells (GI50 in nM range).544
This is in contrast to free MMAE or MMAF, whose cytotoxicities were independent of Gb3
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Figure 27. Chemical structures of monomethyl auristatin E (MMAE, 92), monomethyl auristatin F (MMAF, 93),
β-galactosidase activatable folate-targeted conjugate of MMAE (94), wild type (95a) and modified (95b) pH
(low) insertion peptide conjugates of MMAE, Shiga toxin conjugates of MMAE (96) and MMAF (97), and TRAIL-
MMAE conjugate (98). In 94, 95, 96, 97, and 98, MMAE and MMAF are conjugated to the carriers utilizing the
monomethyl nitrogen that is bolded in structures 92 and 93.
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expression. In addition, the activity of the conjugates on Gb3-positive cells was either similar
to (96) or higher (97) than that of the free drugs.544 These conjugates have not yet been tested
in vivo.
Pan et al.545 developed a conjugate of MMAE and the TRAIL with the purpose of over-
coming TRAIL resistance in cell lines expressing the TRAIL-targeted DR4 and DR5 death
receptors. The conjugate termed N109C-vcMMAE was prepared by attachment of MMAE
and TRAIL through a dipeptide (valine-citrulline) moiety (98, Fig. 27) that could be cleaved
by lysosomal cathepsin to release active MMAE.545 This conjugate showed the highest activity
with a GI50 of 63 nM in the TRAIL-resistant MCF-7 cell line.545 Studies demonstrated that
conjugate internalization occurred by TRAIL-death receptor-mediated endocytosis, and that
cell cycle arrest in the G2-M phase could be affected within 8 hr of exposure to the conjugate.545
in vivo studies in a mouse NCI-H460 lung cancer xenograft model demonstrated the ability
of the N109C-vcMMAE conjugate to target the tumors, potentially by taking advantage of
the EPR effect.545 The antitumor efficacy of the conjugate was not evaluated in this animal
model.
Temming et al.546 developed arginine-glycine-aspartic acid (RGD)-targeted albumin car-
riers for MMAE. Specifically, MMAE-human albumin conjugates 99a and 100a (Fig. 28)
decorated with cyclic c(RGDfK) peptides were used to target and cause apoptosis of ανβ3-
integrin-expressing angiogenic endothelial cells, thereby destroying the tumor’s blood supply.546
These conjugates also utilized a valine-citrulline linker to enable intracellular release ofMMAE
from the albumin carrier upon activation by lysosomal cathepsin.546 The two carriers differed
in the use of either a short alkyl chain (99a) or a poly(ethylene glycol) (PEG) spacer (100a) for
attachment of the targeting RGD peptide. Both carriers showed high specificity toward, inter-
nalization into, and growth inhibition (GI50 in nM range) of ανβ3-integrin-expressing human
umbilical vein endothelial cells (HUVEC).546 Preliminary evaluation in a C26 murine colon
carcinoma mouse xenograft model showed that these carriers could preferentially accumulate
on tumor blood vessels as well as inside of tumors within 24 hr of intravenous injection.546 The
antitumor effect of these systems was not evaluated in vivo.
This same group also evaluated RGD-targeted MMAF albumin conjugates.547 As before,
two conjugate designs were tested for each of the two drugs: one that used a PEG chain and
another a short linker for attachment of the targeting RGDmoiety.547 BothMMAF conjugates
(99b and 100b, Fig. 28) showed strong ability to reduce HUVEC cell growth, with GI50 values
of 22–77 nM compared to 65–420 nM for MMAE conjugates.547 Similar trends were observed
in C26 colon cancer cells, with GI50 values of 10–150 nM for MMAF conjugates and 530–
2070 nM for MMAE conjugates.547 Noticeably, RGD-targeted MMAF conjugates 99b and
100b were more effective than free MMAF, demonstrating that the use of active targeting
enabled intracellular delivery of this charged drug into the cells.547 These systems were not
evaluated in vivo.
Recently, the use of activatable cell-penetratingpeptides (ACPP) consistingof apolycationic
cell penetrating peptide (polyarginine) and apolyanionic (polyglutamate) peptide that are joined
by a MMP-cleavable linker was used for the delivery of MMAE.548 MMAE was covalently
conjugated to the polyanionic portion of an ACPP using a linker that could be cleaved by
lysosomal cathepsin B.548 The ACPP was further targeted to ανβ3-integrin-expressing cells
using cyclic RGD (101, Fig. 28). in vitro studies showed that the targeted peptide was readily
uptaken by a number of human cancer cell lines.548 In addition, in vivo studies inMDA-MB-231
mouse xenograft and in immunocompetent syngenic Py230 murine models demonstrated that
the RGD-targetedMMAE-ACPP conjugate 101 controlled tumor growthmore effectively than
either free MMAE or an MMAE-ACPP conjugate targeted with a sham RAD peptide.548
The use of the MMAE-ACPP conjugate 101 as a radiosensitizer for combination
chemo/radiotherapy was investigated by the same group.549 RGD-targeted MMAE–ACPP
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Figure 28. Chemical structures of c(RGDfK)-targeted conjugates of MMAE and MMAF to albumin using short
alkyl chain linker (99a and 99b) or a poly(ethylene glycol) spacer (100a and 100b), and activatable cell-
penetrating peptide conjugate of MMAE (101). In all of these structures, MMAE and MMAF are conjugated
to the carriers utilizing the monomethyl nitrogen that is bolded in structures 92 and 93.
conjugate 101 was shown to sensitize human colorectal and pancreatic cancer cells to radia-
tion, resulting in increased DNA damage upon dual treatment.549 Studies in mouse xenograft
models with PANC-1 and HCT-116 tumors showed that the targeted conjugate paired with
ionizing radiation provided enhanced tumor regression than radiation alone, free MMAE, or
MMAE in combination with radiation.549
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As described, nanomedicine formulations promise to improve the activity and safety of
mollusk-derived anticancer agents by increasing the payload and specificity of these agents
toward cancer cells. While not many types of nanomedicines have been explored as of yet for
the targeted delivery of mollusk-derived anticancer agents, and even fewer evaluated for in vivo
therapeutic efficacy, the few systems reported to date all showed improvements in solubility,
targeting ability, or therapeutic efficacy compared to the free drugs. We therefore believe that
there is a great opportunity for further development in this field that could enable clinical
advance of these active therapeutic agents in the future.
6. THE PROBLEM OF SUPPLY OF MOLLUSK-DERIVED ANTICANCER AGENTS
Usually, chemists working in a marine natural product laboratory isolate only a few milligrams
of apromising anticancer compoundof novel structure. In the case ofmarinemollusks, bioactive
metabolites are usually available in very small amounts—often less than 1 mg—due either to
compound’s low natural abundance in these organisms or the difficulty of sampling mollusk
biomass. Only small amounts of pure compounds are required for preliminary in vitro screening
in cancer cell lines. In contrast, the preclinical evaluation including studies in in vivo rodent
models often require over 100 mg of a pure compound. Subsequently, grams to hundreds
of grams are usually needed to progress satisfactorily toward clinical trials. Finally, when
a compound is commercialized as a pharmaceutical, kilograms of the pure compound are
required to supply drug production.220,550,551 Due to this, for many years the major perception
in the medical and in general scientific communities has been that marine active agents are not
directly feasible for further development.552 This was true indeed in the past. In recent years,
however, the application and combination of novel techniques in harvest/culture and isolation
processes, the increased knowledge of genomics, andmajor advances in chemical synthesis have
enabled the large-scale production of several marine natural products.110,220,550,551
What strategies can be utilized to scale up the production of mollusk-derived anticancer
compounds? In principle, similar to other invertebrates, this may be performed by large-scale
culture including mariculture (growth of the organism in its natural environment) and aqua-
culture (under artificial conditions). However, due to critical environmental parameters (tem-
perature, pH, light cycle) and nutrition issues,553–555 the cultivation or maintenance of mollusk
specimens is very difficult and often impossible. Although large-scale cultivation has been
widely applied to bivalves for food production556 and significant advances have been achieved
in the larviculture and grow out of marine snails for human consumption,557,558 the cultivation
of mollusks for biotechnological applications is yet to be addressed. To date, the only suc-
cessful example is the production of the sea slug Aplysia californica, which is the well-known
model organism widely used in neuroscience.559 In addition, if a compound comes from the
diet including microorganisms,110 the proper source has to be identified for its production.
Therefore, for almost all mollusk-derived products, the only feasible route to overcome
the supply problem is chemical synthesis. Synthesis provides additional advantages; in fact, it
may not only provide corroboration for the structural assignment, but also may lead to the
production of valuable intermediates and analogues to be used for SAR studies.560 Synthetic
strategies also include the development of derivatives with more manageable properties, or
the design of a pharmacophore of reduced complexity, which can be synthesized more easily.
For example, the production of kahalalide F for its use in clinical trials was developed using
solid-phase peptide chemistry techniques by PharmaMar and according to the same synthetic
procedure, more than 150 analogues were prepared for SAR studies.263,561,562 This synthesis
reported by Jimenez et al.563 is illustrated in Figure 29 and described next.
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Figure 29. Synthesis of Kahalalide F utilized for its production for clinical trials using solid-phase peptide
chemistry. Alloc, allyloxycarbonyl; DIEA, N,N-diisopropylethylamine; DIPCDI, N,N’-diisopropylcarbodiimide;
DMAP, 4-dimethylaminopyridine; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; Fmoc, fluoromethy-
loxycarbonyl chloride; HATU, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hex-
afluorophosphate, HOAT, 1-hydroxy-7-azabenzotriazole; HOBt, 1-hydroxybenzotriazole; Pd(PPh3)4, tetrakis
(triphenylphosphine)palladium(0); PhSiH3, phenylsilane; t-Bu, tert-butyl; TFA, trifluoroacetic acid; (Z)-Dhb, a,b-
didehydro-a-aminobutyric acid.
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This solid-phase synthesis was based on an orthogonal protecting system employing
chlorotrityl chloride as resin (Cl-TrtCl-resin, R1, Fig. 29). Resin R1, was converted to H-D-Val
resinR2 using Fmoc-D-Val-OH andDIEA followed by Fmoc removal. A sequential incorpora-
tion of D-allo-Ile, D-allo-Thr, and D-allo-Ile derivatives using Fmoc/t-Bu andDIPCDI/HOBt
reagent mixture followed by esterication with allo-Val-OH using DIPCDI/DMAP produced
tetrapeptide resin R3. This was then converted to decapeptide resin R5 by chain elongation
through a sequential addition of six amino acids. The N-terminus was then capped with 5-
methylhexanoic acid using the Fmoc removal protocol, Fmoc/t-Bu strategy, and the coupling
reagentmixtureDIPCDI/HOBt.ResinR7was synthesized by twomethods. InmethodA, tride-
capeptideR6was prepared fromR5 by side chain elongation using first Pd(PPh3)4 and PhSiH3,
followed by treatment with FmocThr-OH and HATU/DIEA and Fmoc removal. Next, the
reaction mixture was treated with Alloc-LPhe-OH and HATU/DIEA to yield R6. The prepa-
ration of R6 was followed by selective synthesis of (Z)-Dhb on the resin by Fukase’s conditions
(EDC and CuCl) to give R7. In method B, the dipeptide (Alloc-Phe-(Z)-Dhb-OH) was directly
added to R5 using Pd(PPh3)4, PhSiH3, Alloc-LPhe-ZDhb-OH, and DIPCDI/HOAt to yield
R7. Resin R7 was converted to depsipeptide resin R8 by removal of Alloc group in R7 with
Pd(PPh3)4 and PhSiH3, followed by peptide release from the resin using TFA/CH2Cl2 (1:99)
mixture. The macrocyclization of peptide P8 with HOBt/DIPEA/DIPCDI and the removal
of the side chain protecting groups using TFA/H2O (19:1) mixture afforded kahalalide F (15a;
Fig. 6; Table II).
The synthetic methods performed to produce dolastatins217 have led to a number of novel
intermediate substances such as auristatins and to antibody–drug conjugates currently in Phases
I to III clinical trials.166,222,564
For an increasing number of synthetically challenging anticancer compounds from mol-
lusks the supply problem has been solved through semisynthesis by starting from a more
accessible precursor—typically of microbial origin. An example is Zalypsis R© (PM00104, 84b),
which was synthesized by workers at PharmaMar (Madrid, Spain) using methodologies related
to the trabectedin synthesis from safracin B.565 Moving to more chemically complex molecules,
the challenges associated with their total synthesis are significant but not insurmountable.
Today, chemists can synthesize organic compounds—natural and designed—of all types of
structural architectures.566 In the last few decades a surge in total synthesis endeavors around
the world in constructing natural products of medicinal importance against cancer has led to a
remarkable collection of achievements that covers a wide ranging landscape of molecular and
stereochemical complexity and diversity.566
Of course, scalability of the entire synthetic process leading to the target compound re-
mains a crucial feature.567 Historically, the pharmaceutical industry’s acceptance of structurally
complex natural products or natural product derivatives supplied commercially through total
synthesis has been low for a variety of reasons, but the situation is slowly changing. The accessi-
bility of target activemolecules by simple scalable routes is based on a series of factors including
step count, level of complexity of the chemistry used, stereochemical control, chemical stability
of each process and intermediate, overall yield, and operational complexities, among others.
An increasing number of potential anticancer marine natural products are now prepared in
a scalable fashion.567 The most significant example of a large-scale total synthesis that has
solved a major supply issue is that of eribulin mesylate (Halaven R©) inspired by the marine
natural product halichondrin B.568 Eribulin is a macrocyclic ketone with 36 atoms, 19 of which
are stereogenic centers, that represents the most structurally complex, nonpeptidic, and fully
synthetic drug on the market today. However, it should be taken into consideration that the
“supply issue” is only one of the crucial aspects in anticancer drug development. The so-called
“valley of death” that is the gap between the discovery of the active principle and its entering
clinical trials is a highly complex problem where numerous driving forces—scientific, financial,
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and other economic and nontechnical factors—play a role.569 Scientific critical tasks include
drug production, of course, but also tumor physiology, drug pharmacokinetics, preclinical
models, drug delivery, and clinical translation. The lack of common methods to address these
aspects by industrial pharmaceutical companies (Pharma) and academic scientists (Academia)
is a fundamental point. Only a greater Pharma-Academia collaboration could overcome the
barrier of the valley of death in the development of new effective anticancer therapies.570
7. CONCLUSIONS: WHAT ARE THE MOST PROMISING MOLLUSK-DERIVED
ANTICANCER COMPOUNDS?
Of note, no “recent” mollusk-derived compounds have attained late Phase II or Phase III
clinical trials in oncology. However, we think that several “mollusk-derived” compounds merit
further consideration.
In terms of in vivo activity, we think that a compound forwhich clear evidence of activity has
been demonstrated in various models (including aggressive metastatic) has a greater probability
to move toward clinical trials than a compound that has not been assayed in vivo, displays no
activity in vivo, or whose in vivo activity has been demonstrated, for example, in ascitic models
of mouse leukemia, which are by far too chemosensitive and not at all representative of the
clinical situation.
It is interesting that several dolastatins (or their derivatives) displayed marked in vivo
anticancer activity in multiple preclinical models (murine syngeneic as well as human xenograft
models), but failed to demonstrate actual anticancer activity in Phase II clinical trials. It
is important to keep in mind that tumor doubling times markedly differ between murine
tumor models (days to weeks) and human cancers (weeks to years).571 Dolastatins are tubulin
inhibitors, which are known to be more effective against rapidly proliferating cells. Human
orthotopic xenografts in most cases develop much more rapidly in immunocompromised or
immunodeficient mice than their counterparts developing in humans. Furthermore, dolastatins
are tubulin inhibitors without other reported targets in the literature (at least to the best
of our knowledge). They are cytotoxic proapoptotic compounds and substrates of the P-gp,
which makes them unable to overcome resistance to proapoptotic stimuli or circumvent the
MDR phenotype. It is important to emphasize once again that cancers associated with dismal
prognoses, including metastatic cancers, display resistance to proapoptotic stimuli.
According to data we report in the current review, we estimate that the following com-
pounds are “promising” and should be pursued further: dolastatin 16 (9), chlorolissoclimide
(33b), doliculide (46), ulapaulideA (60a), kabiramideC (61a), halichondramide-relatedmetabo-
lites (62a-62c), aplyronine A (64a), sphinxolide (66), latrunculin A (67a), hectochlorin (75a),
lamellarin D (76), and spisulosine (87). We urge the readers of the current review to perform
experiments designed to address the major “biological cancer characteristics” we detailed in the
Introduction to create a stronger basis for the selection of promising anticancer agents derived
from marine mollusks.
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